Can B (CANB) 10-K 14 Apr 21 2020 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2020	Mar. 25, 2021
Cover [Abstract]
Entity Registrant Name	Can B Corp
Entity Central Index Key	0001509957
Document Type	10-K
Document Period End Date	Dec. 31, 2020
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Entity Shell Company	false
Entity Public Float	$ 3,758,316
Entity Common Stock, Shares Outstanding		16,667,655
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2020

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 457,798	$ 46,540
Accounts receivable, less allowance for doubtful accounts of $485,848 and $0, respectively	2,003,064	1,251,609
Inventory	344,954	784,497
Note Receivable	2,898	24,268
Prepaid expenses - current	1,209,126	1,279,901
Total current assets	4,017,840	3,386,815
Property and equipment, at cost less accumulated depreciation of $239,650 and $116,555, respectively	994,979	1,075,242
Other assets:
Deposit - noncurrent	21,287	21,287
Prepaid expenses - noncurrent	7,405	1,179,929
Other receivable - noncurrent	12,910	58,206
Intangible assets, net of accumulated amortization of $236,431 and $202,521, respectively	523,009	1,339,907
Goodwill	55,849	55,849
Right-of-Use Asset, net of amortization of $45,086 and $6,280, respectively	58,174	96,980
Total other assets	678,634	2,752,158
Total assets	5,691,453	7,214,215
Current liabilities:
Accounts payable	153,640	226,467
Accrued officers' compensation	147,133	144,363
Other accrued expenses payable	53,362	61,557
Notes and loans payable	1,827,531	35,000
Current portion of lease liability	43,506	38,281
Total current liabilities	2,225,172	505,668
Long-term liabilities
Non-current portion of lease liability	15,492	58,998
Notes and loans payable	194,940
Total long-term liabilities	210,432	58,998
Total liabilities	2,435,604	564,666
Commitments and contingencies (Notes 14)
Stockholders' equity:
Common stock, no par value; authorized 1,500,000,000 shares, issued and outstanding 5,544,590 and 2,680,937 shares, respectively	26,111,978	24,323,712
Treasury stock	(572,678)
Additional Paid-in capital	872,976	872,976
Additional Paid-in capital - Stock Options (Note 11)	962,323	583,200
Additional Paid-in capital - Warrants	728,100
Accumulated deficit	(30,386,024)	(24,669,513)
Total stockholders' equity	3,255,849	6,649,549
Total liabilities and stockholders' equity	5,691,453	7,214,215
Series A Preferred Stock [Member]
Stockholders' equity:
Preferred stock, authorized 5,000,000 shares:	5,539,174	5,539,174
Series B Preferred Stock [Member]
Stockholders' equity:
Preferred stock, authorized 5,000,000 shares:

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Allowance for doubtful accounts	$ 485,848	$ 0
Accumulated depreciation, property and equipment	239,650	116,555
Amortization of intangible assets	236,431	202,521
Amortization of right-of-use Asset	$ 45,086	$ 6,280
Preferred stock, shares authorized	5,000,000	5,000,000
Common stock, par value
Common stock, shares authorized	1,500,000,000	1,500,000,000
Common stock, shares issued	5,544,590	2,680,937
Common stock, shares outstanding	5,544,590	2,680,937
Series A Preferred Stock [Member]
Preferred stock, shares authorized	20	20
Preferred stock, par value
Preferred stock, shares issued	20	20
Preferred stock, shares outstanding	20	20
Series B Preferred Stock [Member]
Preferred stock, shares authorized	500,000	500,000
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Revenues
Total Revenues	$ 1,709,669	$ 2,305,503
Cost of product sales	278,062	598,584
Gross Profit	1,431,607	1,706,919
Operating costs and expenses:
Officers and director's compensation (including stock-based Compensation of $1,589,224 and $1,587,060, respectively	2,077,713	2,639,711
Consulting fees (including stock-based compensation of 669,956 and 2,831,232, respectively)	778,062	3,014,329
Advertising expense	519,922	333,441
Hosting expense	22,781	13,034
Rent expense	234,790	246,968
Professional fees	533,213	287,441
Depreciation of property and equipment	16,475	12,627
Amortization of intangible assets	658,910	142,093
Reimbursed Expenses	87,718	242,585
Other	876,431	667,097
Total operating expenses	5,806,015	7,599,326
Loss from operations	(4,374,408)	(5,892,407)
Other income (expense):
Gain (loss) on disposal of assets - net	(374,116)
Loss on investment	(40,000)
EIDL Grant	10,000
Interest income (forfeited) - net	(3,068)	2,524
Interest expense (including amortization finance cost of $725,287 and $0, respectively	(931,615)	(8,793)
Other income (expense) - net	(1,338,799)	(6,269)
Loss before provision for income taxes	(5,713,207)	(5,898,676)
Provision for income taxes	3,304	2,084
Loss and comprehensive loss	$ (5,716,511)	$ (5,900,760)
Net loss per common share - basic	$ (1.62)	$ (2.87)
Net loss per common share - diluted	$ (1.36)	$ (2.20)
Weighted average common shares outstanding -
Basic	3,534,739	2,058,525
Diluted	4,201,419	2,687,383
Product Sales [Member]
Revenues
Total Revenues	$ 1,708,419	$ 2,304,303
Service Revenue [Member]
Revenues
Total Revenues	$ 1,250	$ 1,200

Consolidated Statements of Op_2

Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Stock-based compensation	$ 2,259,180	$ 4,397,478
Amortization of finance cost	725,287	0
Consulting Fees [Member]
Stock-based compensation	669,956	2,831,232
Officers and Directors [Member]
Stock-based compensation	$ 1,589,224	$ 1,587,060

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Deficiency - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Preferred Stock A [Member]
Balance	$ 5,539,174	$ 4,557,424
Balance, shares	20	18
Issuance of Series A Preferred stock pursuant to employment agreement		$ 992,250
Issuance of Series A Preferred stock pursuant to employment agreement, shares		3
Issuance of common stock for retirement of Series A Preferred Stock		$ (10,500)
Issuance of common stock for retirement of Series A Preferred Stock, shares		(1)
Issuance of common stock for retirement of Series B Preferred Stock
Issuance of common stock for retirement of Series B Preferred Stock, shares
Sale of common stock
Sale of common stock, shares
Issuance of common stock in 2019 for acquisition of technology
Issuance of common stock in 2019 for acquisition of technology, shares
Issuance of common stock in 2019 for acquisition of inventory
Issuance of common stock in 2019 for acquisition of inventory, shares
Issuance of common stock in 2019 for satisfaction of accrued salaries
Issuance of common stock in 2019 for satisfaction of accrued salaries, shares
Issuance of common stock in 2019 for compensation and services rendered
Issuance of common stock in 2019 for compensation and services rendered, shares
Issuance of common stock in 2020 for services rendered
Issuance of common stock in 2020 for 300:1 reverse stock split rounding
Issuance of common stock in 2020 for 300:1 reverse stock split rounding, shares
Issuance of common stock in 2020 pursuant to First Fire note agreement
Issuance of common stock in 2020 pursuant to First Fire note agreement, shares
Issuance of common stock in 2020 pursuant to Labrys Fund Equities note agreement
Issuance of common stock in 2020 pursuant to Labrys Fund Equities note agreement, shares
Issuance of common stock in 2020 pursuant to Eagle Equities note agreement
Issuance of common stock in 2020 pursuant to Eagle Equities note agreement, shares
Issuance of common stock in 2020 pursuant to Arena note agreement
Issuance of common stock in 2020 pursuant to Arena note agreement, shares
Issuance of common stock in 2020 for acquisition of intangible assets
Issuance of common stock in 2020 for acquisition of intangible assets, shares
Issuance of common stock in 2020 for compensation
Issuance of common stock in 2020 for compensation, shares
Issuance of common stock in 2020 for interest
Issuance of common stock in 2020 for interest, shares
Issuance of common stock in 2020 for inventory
Issuance of common stock in 2020 for inventory, shares
Treasury stock acquired in 2020
Treasury stock acquired in 2020, shares
Net loss
Balance	$ 5,539,174	$ 5,539,174
Balance, shares	20	20
Preferred Stock B [Member]
Balance		$ 479
Balance, shares		499,958
Issuance of Series A Preferred stock pursuant to employment agreement
Issuance of common stock for retirement of Series B Preferred Stock		$ (479)
Issuance of common stock for retirement of Series B Preferred Stock, shares		(499,958)
Sale of common stock
Issuance of common stock in 2020 for services rendered
Issuance of common stock in 2020 for 300:1 reverse stock split rounding
Issuance of common stock in 2020 for 300:1 reverse stock split rounding, shares
Issuance of common stock in 2020 pursuant to First Fire note agreement
Issuance of common stock in 2020 pursuant to First Fire note agreement, shares
Issuance of common stock in 2020 pursuant to Labrys Fund Equities note agreement
Issuance of common stock in 2020 pursuant to Labrys Fund Equities note agreement, shares
Issuance of common stock in 2020 pursuant to Eagle Equities note agreement
Issuance of common stock in 2020 pursuant to Eagle Equities note agreement, shares
Issuance of common stock in 2020 pursuant to Arena note agreement
Issuance of common stock in 2020 pursuant to Arena note agreement, shares
Issuance of common stock in 2020 for acquisition of intangible assets
Issuance of common stock in 2020 for acquisition of intangible assets, shares
Issuance of common stock in 2020 for compensation
Issuance of common stock in 2020 for compensation, shares
Issuance of common stock in 2020 for interest
Issuance of common stock in 2020 for interest, shares
Issuance of common stock in 2020 for inventory
Issuance of common stock in 2020 for inventory, shares
Treasury stock acquired in 2020
Treasury stock acquired in 2020, shares
Net loss
Balance
Balance, shares
Preferred Stock C [Member]
Balance
Balance, shares
Issuance of Series A Preferred stock pursuant to employment agreement
Issuance of common stock for retirement of Series B Preferred Stock
Issuance of common stock for retirement of Series B Preferred Stock, shares
Sale of common stock
Issuance of common stock in 2020 for services rendered
Issuance of common stock in 2020 for services rendered, shares
Issuance of common stock in 2020 for 300:1 reverse stock split rounding
Issuance of common stock in 2020 for 300:1 reverse stock split rounding, shares
Issuance of common stock in 2020 pursuant to First Fire note agreement
Issuance of common stock in 2020 pursuant to First Fire note agreement, shares
Issuance of common stock in 2020 pursuant to Labrys Fund Equities note agreement
Issuance of common stock in 2020 pursuant to Labrys Fund Equities note agreement, shares
Issuance of common stock in 2020 pursuant to Eagle Equities note agreement
Issuance of common stock in 2020 pursuant to Eagle Equities note agreement, shares
Issuance of common stock in 2020 pursuant to Arena note agreement
Issuance of common stock in 2020 pursuant to Arena note agreement, shares
Issuance of common stock in 2020 for acquisition of intangible assets
Issuance of common stock in 2020 for acquisition of intangible assets, shares
Issuance of common stock in 2020 for compensation
Issuance of common stock in 2020 for compensation, shares
Issuance of common stock in 2020 for interest
Issuance of common stock in 2020 for interest, shares
Issuance of common stock in 2020 for inventory
Issuance of common stock in 2020 for inventory, shares
Treasury stock acquired in 2020
Treasury stock acquired in 2020, shares
Net loss
Balance
Balance, shares
Common Stock [Member]
Balance	$ 24,323,712	$ 16,624,557
Balance, shares	2,680,937	1,468,554
Issuance of Series A Preferred stock pursuant to employment agreement
Issuance of common stock for retirement of Series B Preferred Stock		$ 479
Issuance of common stock for retirement of Series B Preferred Stock, shares		250,131
Sale of common stock	$ 300,000	$ 3,296,700
Sale of common stock, shares	600,000	379,555
Issuance of common stock in 2019 for acquisition of technology		$ 932,000
Issuance of common stock in 2019 for acquisition of technology, shares		68,580
Issuance of common stock in 2019 for acquisition of inventory		$ 487,500
Issuance of common stock in 2019 for acquisition of inventory, shares		125,000
Issuance of common stock in 2019 for satisfaction of accrued salaries		$ 33,153
Issuance of common stock in 2019 for satisfaction of accrued salaries, shares		2,227
Issuance of common stock in 2019 for compensation and services rendered		$ 2,938,823
Issuance of common stock in 2019 for compensation and services rendered, shares		353,557
Issuance of common stock in 2020 for services rendered	$ 584,338
Issuance of common stock in 2020 for 300:1 reverse stock split rounding
Issuance of common stock in 2020 for 300:1 reverse stock split rounding, shares	2,460
Issuance of common stock in 2020 pursuant to First Fire note agreement	$ 357,030
Issuance of common stock in 2020 pursuant to First Fire note agreement, shares	313,032
Issuance of common stock in 2020 pursuant to Labrys Fund Equities note agreement	$ 80,182
Issuance of common stock in 2020 pursuant to Labrys Fund Equities note agreement, shares	142,545
Issuance of common stock in 2020 pursuant to Eagle Equities note agreement	$ 8,745
Issuance of common stock in 2020 pursuant to Eagle Equities note agreement, shares	20,000
Issuance of common stock in 2020 pursuant to Arena note agreement	$ 129,580
Issuance of common stock in 2020 pursuant to Arena note agreement, shares	409,417
Issuance of common stock in 2020 for acquisition of intangible assets	$ 217,012
Issuance of common stock in 2020 for acquisition of intangible assets, shares	285,000
Issuance of common stock in 2020 for compensation	$ 41,625
Issuance of common stock in 2020 for compensation, shares	30,000
Issuance of common stock in 2020 for interest	$ 77,775
Issuance of common stock in 2020 for interest, shares	185,000
Issuance of common stock in 2020 for inventory	$ 491,979
Issuance of common stock in 2020 for inventory, shares	478,715
Treasury stock acquired in 2020
Treasury stock acquired in 2020, shares	(543,715)
Net loss
Balance	$ 26,111,978	$ 24,323,712
Balance, shares	5,544,590	2,680,937
Treasury Stock [Member]
Balance
Balance, shares
Issuance of Series A Preferred stock pursuant to employment agreement
Issuance of common stock for retirement of Series B Preferred Stock
Sale of common stock
Issuance of common stock in 2020 for services rendered
Issuance of common stock in 2020 for 300:1 reverse stock split rounding
Treasury stock acquired in 2020	$ (560,000)
Treasury stock acquired in 2020, shares	543,715
Net loss
Balance	$ (572,678)
Balance, shares	543,715
Additional Paid-in Capital [Member]
Balance	$ 1,456,176	$ 1,075,176
Issuance of Series A Preferred stock pursuant to employment agreement
Issuance of common stock for retirement of Series B Preferred Stock
Sale of common stock
Issuance of common stock in 2020 for services rendered
Issuance of common stock in 2020 for 300:1 reverse stock split rounding
Stock options	379,123	381,111
Warrants	728,100
Net loss
Balance	2,563,399	1,456,176
Accumulated Deficit [Member]
Balance	(24,669,513)	(18,768,753)
Issuance of Series A Preferred stock pursuant to employment agreement
Issuance of common stock for retirement of Series B Preferred Stock
Sale of common stock
Issuance of common stock in 2020 for services rendered
Issuance of common stock in 2020 for 300:1 reverse stock split rounding
Net loss	(5,716,511)	(5,900,760)
Balance	(30,386,024)	(24,669,513)
Balance	6,649,549	3,488,883
Issuance of Series A Preferred stock pursuant to employment agreement		992,250
Issuance of common stock for retirement of Series A Preferred Stock		76,704,954
Issuance of common stock for retirement of Series B Preferred Stock
Sale of common stock		3,296,700
Issuance of common stock in 2019 for acquisition of technology		932,000
Issuance of common stock in 2019 for acquisition of inventory		487,500
Issuance of common stock in 2019 for satisfaction of accrued salaries		33,153
Issuance of common stock in 2019 for compensation and services rendered		$ 2,938,823
Issuance of common stock in 2020 for services rendered	584,338
Issuance of common stock in 2020 for services rendered, shares
Issuance of common stock in 2020 for 300:1 reverse stock split rounding
Issuance of common stock in 2020 pursuant to First Fire note agreement	357,030
Issuance of common stock in 2020 pursuant to Labrys Fund Equities note agreement	80,182
Issuance of common stock in 2020 pursuant to Eagle Equities note agreement	8,745
Issuance of common stock in 2020 pursuant to Arena note agreement	129,580
Issuance of common stock in 2020 for acquisition of intangible assets	217,012
Issuance of common stock in 2020 for compensation	$ 41,625
Issuance of common stock in 2020 for compensation, shares
Issuance of common stock in 2020 for interest	$ 77,775
Issuance of common stock in 2020 for inventory	491,979
Treasury stock acquired in 2020	(560,000)
Stock options	379,123	$ 381,111
Warrants	728,100
Net loss	(5,716,511)	(5,900,760)
Balance	$ 3,255,849	$ 6,649,549

Consolidated Statements of St_2

Consolidated Statements of Stockholders' Deficiency (Parenthetical)	Mar. 06, 2020	Mar. 02, 2020	Jun. 04, 2013	Dec. 31, 2020
Statement of Stockholders' Equity [Abstract]
Reverse stock, description	300:1 reverse stock split	300-to-1 reverse stock split	1-for-10 reverse stock split	300:1 reverse stock split

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Operating Activities:
Net loss	$ (5,716,511)	$ (5,900,760)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation, net of prepaid stock- based consulting fees	2,259,180	4,397,478
Stock-based interest expense	451,680
Gain (loss) on disposal of asset - net	374,116
Depreciation of property and equipment	16,475	12,627
Amortization of intangible assets	658,910	142,093
Amortization of debt discounts	273,607
Bad debt expense	270,919	253,483
Changes in operating assets and liabilities:
Accounts receivable	(1,022,374)	(1,465,920)
Inventory	931,523	(209,893)
Prepaid expenses	(10,797)	(4,760)
Security deposit		27,439
Other receivable	57,974	(58,206)
Right-of-use asset	525	299
Accounts payable	(72,827)	153,408
Accrued officer's compensation	2,770	144,363
Other accrued expenses payable	(8,195)	17,777
Net cash used in operating activities	(1,947,091)	(2,413,420)
Investing Activities:
Note receivable	21,370	(4,879)
Fixed assets additions	(50,219)	(1,105,403)
Proceeds from disposal of asset	3,600
Intangible assets additions		(550,000)
Net cash used in investing activities	(25,249)	(1,660,282)
Financing Activities:
Proceeds received from notes and loans payable	4,521,618	35,000
Repayments of notes and loans payable	(1,359,900)	(19,205)
Note payable finance cost	(518,120)
Proceeds from sale of common stock	300,000	3,296,700
Acquisition of treasury stock	(560,000)
Net cash provided by financing activities	2,383,598	3,312,495
Increase (Decrease) in cash and cash equivalents	411,258	(761,207)
Cash and cash equivalents, beginning of period	46,540	807,747
Cash and cash equivalents, end of period	457,798	46,540
SUPPLEMENTAL CASH FLOW INFORMATION:
Income taxes paid	3,304	2,084
Interest paid	206,328	8,793
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Issuance of common stock in acquisition of inventory	491,980	487,500
Issuance of common stock in acquisition of intangible assets	217,011	404,345
Amortization of prepaid issuance of common Stock for services rendered	1,254,096	121,000
Issuance of common stock in acquisition of note payable (commitment shares)	929,734
Issuance of common stock in acquisition of note payable (interest expense)	451,680
Issuance of common stock in satisfaction of officer's compensation		47,563
Issuance of common stock in conversion of Series A Preferred Stock		10,500
Issuance of common stock in retirement of Series B Preferred Stock		$ 479

Organization and Description of

Organization and Description of Business	12 Months Ended
	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Description of Business	NOTE 1 – Organization and Description of Business Can B̅ Corp. was originally incorporated as WrapMail, Inc. (“WRAP”) in Florida on October 11, 2005. Effective January 5, 2015, WRAP acquired 100% ownership of Prosperity Systems, Inc. (“Prosperity”), a New York corporation incorporated on April 2, 2008. The Company is in the process of dissolving Prosperity. The Company acquired 100% of the membership interests in Pure Health Products, LLC, a New York limited liability company (“PHP” or “Pure Health Products”) effective December 28, 2018. The Company’s durable equipment products, such as sam® units with and without CBD infused pads, are marketed and sold through its wholly-owned subsidiaries, Duramed Inc. (incorporated on November 29, 2018) and Duramed MI LLC fka DuramedNJ, LLC(incorporated on May 29, 2019) (collectively, “Duramed”). Duramed began operating on or about February1, 2019. The Company’s hemp farming business is run through Green Grow Farms, Inc. (“Green Grow Farms”), which was acquired in August, 2019. The Company’s other subsidiary companies did not have operations in 2020. Effective December 27, 2010, WRAP effected a 10-for-1 forward stock split of its common stock. Effective June 4, 2013, WRAP effected a 1-for-10 reverse stock split of its common stock. Effective March 6, 2020 Can B̅ Corp effected a 300:1 reverse stock split of its common stock. On May 15, 2017, WRAP changed its name to Canbiola, Inc. On January 16, 2020 Canbiola, Inc. changed its name to Can B̅ Corp. (the “Company”, “we”, “us”, “our”, “CANB”, “Can B̅” or “Registrant”). Can B̅ specializes in the production and sale of a variety of hemp-derived cannabidiol (“CBD”) products such as oils, creams, moisturizers, isolate, gel caps, spa products, and concentrates and non-hemp lifestyle products. Can B̅ is developing its own line of proprietary products as well as seeking synergistic value through acquisitions in the hemp industry. Can B̅ aims to be the premier provider of the highest quality hemp CBD products on the market through sourcing the very best raw material and developing a variety of products we believe will improve people’s lives in a variety of areas. For the periods presented, the assets, liabilities, revenues, and expenses are those of CAN B and its operational subsidiaries. Financial information for PHP, Duramed and Green Grow Farms in the periods have been consolidated with the Company’s financials. Prosperity, Imbibe Wellness Solutions, LLC fka Radical Tactical and Pivt labs, LLC fka NY Hemp Depot had no activity for the periods presented.

Going Concern Uncertainty

Going Concern Uncertainty	12 Months Ended
	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern Uncertainty	NOTE 2 – Going Concern Uncertainty The consolidated financial statements have been prepared on a “going concern” basis, which contemplates the realization of assets and liquidation of liabilities in a normal course of business. As of December 31, 2020, the Company had cash and cash equivalents of $457,798 and a working capital of $1,118,857. For the years ended December 31, 2020 and 2019, the Company had net loss of $5,851,512 and $5,900,760, respectively. As a result, cash flows may not be sufficient to meet obligations or sustain operations. The Company has plans to improve its financial condition and cash flow. Management believes these plans will alleviate the going concern issue. These plans include: ○ Satisfying accrued but unpaid compensation through the issuance of stock. ○ From January 1, 2021 through March 31,2021 the Company raised $2,716,000 from sale of common stock. ○ The Company intends to raise additional capital from the sale of common stock. ○ Increase sales of products through additional product offerings. ○ Increase product sales through expanded marketing programs. The consolidated financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	NOTE 3 – Summary of Significant Accounting Policies (a) Principles of Consolidation The consolidated financial statements include the accounts of CANB and its wholly-owned subsidiaries, Pure Health Products, Duramed, Prosperity Radical Tactical and Green Grow Farms. All intercompany balances and transactions have been eliminated in consolidation. (b) Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. (c) Fair Value of Financial Instruments The Company’s financial instruments consist of cash and cash equivalents, accounts receivable, notes receivable, notes and loans payable, accounts payable, and accrued expenses payable. Except for the noncurrent note receivable, the fair value of these financial instruments approximate their carrying amounts reported in the balance sheets due to the short term maturity of these instruments. Based on comparable instruments with similar terms, the fair value of the noncurrent note receivable approximates its carrying value. Pursuant to ASC 820, Fair Value Measurements and Disclosures, an entity is required to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value: Level 1 - applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. Level 2 - applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data. Level 3 - applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. (d) Cash and Cash Equivalents The Company considers all liquid investments purchased with a maturity of three months or less to be cash equivalents. (e) Accounts receivable Accounts receivable are presented in the balance sheet net of the allowance for doubtful accounts. Accounts receivable are written off when they are determined to be uncollectible. The allowance for doubtful accounts is estimated based on the Company’s historical losses, the existing economic conditions in the industry, and the financial stability of its customers. Bad debt expense was $270,919 and $0 for the periods ended December 31, 2020 and 2019. (f) Inventory Inventories consist of raw materials and finished goods and are stated at the lower of cost or net realizable value. Cost is principally determined using the first-in, first-out (FIFO) method. (g) Prepaid expenses Prepaid expenses include stock-based officer, employee and consulting compensation of $1,216,531 and $2,459,830 at December 31, 2020 and 2019, respectively. The Company’s policy is to record stock-based compensation as prepaids and expense over the term of employment and consulting agreements. (h) Property and Equipment, Net Property and equipment, net, is stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the respective assets. Maintenance and repairs are charged to operations as incurred. (i) Intangible Assets, Net Intangible assets, net, are stated at cost less accumulated amortization. Amortization is calculated using the straight-line method over the estimated economic lives of the respective assets. (j) Goodwill The Company does not amortize goodwill, but instead tests for impairment at least annually. When conducting the annual impairment test for goodwill, the Company compares the estimated fair value of a reporting unit containing goodwill to its carrying value. If the estimated fair value of the reporting unit is determined to be less than its carrying value, goodwill is reduced, and an impairment loss is recorded. (k) Long-lived Assets The Company reviews long-lived assets held and used, intangible assets with finite useful lives and assets held for sale for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If an evaluation of recoverability is required, the estimated undiscounted future cash flows associated with the asset is compared to the asset’s carrying amount to determine if a write-down is required. If the undiscounted cash flows are less than the carrying amount, an impairment loss is recorded to the extent that the carrying amount exceeds the fair value. (l) Revenue Recognition The Company recognizes revenue in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers, which requires that five basic steps be followed to recognize revenue: (1) a legally enforceable contract that meets criterial standards as to composition and substance is identified; (2) performance obligations relating to provision of goods or services to the customer are identified; (3) the transaction price, with consideration given to any variable, noncash, or other relevant consideration, is determined; (4) the transaction price is allocated to the performance obligations; and (5) revenue is recognized when control of goods or services is transferred to the customer with consideration given, whether that control happens over time or not. Determination of criteria (3) and (4) are based on our management’s judgments regarding the fixed nature of the selling prices of the products and services delivered and the collectability of those amounts. Private Label Customers are wholesale distributors of the Company’s product, under their own wholesale private label brand. The products are made to Company specifications and shipped directly to the wholesaler. The pricing is predicated upon a volume discount negotiated at the time of the placement of the orders. Product is produced and labeled in the Washington manufacturing facility and shipped directly to the Private Label customer who re-distributes to their retail and other customers. The products are fully paid when shipped. Revenue from product sales is recognized when an order has been obtained, the price is fixed and determinable, the product is shipped, title has transferred, and collectability is reasonably assured. The Company’s Duramed Division provides a sam® Pro 2.0 medical device to patients through a doctor program whereby the physician evaluates the patients’ needs for medical necessity, and if determined that the device use would be beneficial, writes a prescription for the patient who signs a rental form, for a 35 day cycle for the unit, that is submitted to Duramed who bills the appropriate insurance company. The insurance company pays the invoice, or a negotiated amount via arbitration, and that revenue is reported as revenue when invoiced to the insurance carrier. The collected amount is reconciled with the invoice amount on a daily basis. (m) Cost of Product Sales The cost of product sale is the total cost incurred to obtain a sale and the cost of the goods sold, and the Company’s policy is to recognize it in the same manner as, and in conjunction with, revenue recognition. Cost of product sale primarily consisted of the costs directly attributable to revenue recognized and includes expenses related to the production, packaging and labeling of our CBD products. (n) Stock-Based Compensation Stock-based compensation is accounted for at fair value in accordance with Accounting Standards Codification (“ASC”) Topic 718, “Compensation – Stock Compensation” (“ASC718”) and ASC 505-50, “Equity – Based Payments to Non-Employees.” In addition to requiring supplemental disclosures, ASC 718 addresses the accounting for share-based payment transactions in which a company receives goods or services in exchange for (a) equity instruments of the company or (b) liabilities that are based on the fair value of the company’s equity instruments or that may be settled by the issuance of such equity instruments. ASC 718 focuses primarily on accounting for transactions in which a company obtains employee services in share-based payment transactions. In accordance with ASC 505-50, the Company determines the fair value of the stock-based payment as either the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. If the fair value of the equity instruments issued is used, it is measured using the stock price and other measurement assumptions as of the earlier of either (1) the date at which a commitment for performance by the counterparty to earn the equity instrument is reached, or (2) the date at which the counterparty’s performance is complete. Options and warrants The fair value of stock options and warrants is estimated on the measurement date using the Black-Scholes model with the following assumptions, which are determined at the beginning of each year and utilized in all calculations for that year: Risk-Free Interest Rate. We utilized the U.S. Treasury yield curve in effect at the time of grant with a term consistent with the expected term of our awards. Expected Volatility. We calculate the expected volatility based on a volatility index of peer companies as we did not have sufficient historical market information to estimate the volatility of our own stock. Dividend Yield. We have not declared a dividend on its common stock since its inception and have no intentions of declaring a dividend in the foreseeable future and therefore used a dividend yield of zero. Expected Term. The expected term of options granted represents the period of time that options are expected to be outstanding. We estimated the expected term of stock options by using the simplified method. For warrants, the expected term represents the actual term of the warrant. Forfeitures. Estimates of option forfeitures are based on our experience. We will adjust our estimate of forfeitures over the requisite service period based on the extent to which actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures will be recognized through a cumulative catch-up adjustment in the period of change and will also impact the amount of compensation expense to be recognized in future periods. (o) Advertising Advertising costs are expensed as incurred and amounted to $519,922 and $333,441 for the years ended December 31, 2020 and 2019, respectively. (p) Research and Development Research and development costs are expensed as incurred. In the period ended December 31, 2020 and 2019 the Company spent $165,000nd $150,000 in research and development which was expenses as spent, respectively. (q) Income Taxes Income taxes are accounted for under the assets and liability method. Current income taxes are provided in accordance with the laws of the respective taxing authorities. Deferred income taxes are provided for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is not more likely than not that some portion or all of the deferred tax assets will be realized. The Company has adopted the provisions required by the Income Taxes topic of the FASB Accounting Standards Codification. The Codification Topic requires the recognition of potential liabilities as a result of management’s acceptance of potentially uncertain positions for income tax treatment on a “more-likely-than-not” probability of an assessment upon examination by a respective taxing authority. The Company believes that it has not taken any uncertain tax positions and thus has not recorded any liability. (r) Net Income (Loss) per Common Share Basic net income (loss) per common share is computed on the basis of the weighted average number of common shares outstanding during the period. Diluted net income (loss) per common share is computed on the basis of the weighted average number of common shares and dilutive securities (such as stock options and convertible securities) outstanding. Dilutive securities having an anti-dilutive effect on diluted net income (loss) per share are excluded from the calculation. For the periods presented, the diluted net loss per share calculation excluded the effect of Series B preferred stocks and stock options outstanding (see Notes 10, 11 and 12). (s) Reverse Stock-Split On March 2, 2020, the Company filed an amendment to its Articles of Incorporation with the Florida Secretary of State to effect a 300-to-1 reverse stock split of its issued and outstanding, but not authorized, shares of Common Stock, as reported in the Company’s definitive Schedule 14C filed with the Securities and Exchange Commission on December 13, 2019. All disclosures of common shares and per common share data in the accompanying financial statements and related notes reflect the reverse stock split for all periods presented. (t) Recent Accounting Pronouncements In 2016, the FASB issued ASU 2016-2 (Topic 842) which establishes a new lease accounting model for lessees. Under the new guidance, lessees will be required to recognize right of use assets and liabilities for most leases having terms of 12 months or more. Effective January 1, 2019, we adopted this new accounting guidance using the effective date transition method, which permits entities to apply the new lease standards using a modified retrospective transition approach at the date of adoption. (u) Reclassifications Certain amounts in the prior year consolidated financial statements have been reclassified to conform to the current year presentation. These reclassification adjustments had no effect on the Company’s previously reported net income.

Inventories

Inventories	12 Months Ended
	Dec. 31, 2020
Inventory Disclosure [Abstract]
Inventories	NOTE 4 – Inventories Inventories consist of: December 31, December 31, Raw materials $ 294,522 $ 708,239 Finished goods 50,432 76,258 Total $ 344,954 $ 784,497

Notes Receivable

Notes Receivable	12 Months Ended
	Dec. 31, 2020
Receivables [Abstract]
Notes Receivable	NOTE 5 – Notes Receivable Notes receivable consist of: December 31, December 31, Note receivable dated November 30, 2015 from Stock Market Manager, Inc, interest at 3% per annum due November 30, 2020 $ - $ 19,389 Note receivable dated February 8,2019 from an employee, weekly installments of $1,200 with interest at 8% per annum. 2,898 4,879 Total 2,898 24,268 Current portion of notes receivable (2,898 ) (24,268 Noncurrent portion of notes receivable $ - $ -

Property and Equipment, Net

Property and Equipment, Net	12 Months Ended
	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	NOTE 6 – Property and Equipment, Net Property and Equipment, net, consist of: December 31, 2020 December 31, 2019 Furniture & Fixtures $ 21,727 $ 19,018 Office Equipment 12,378 12,378 Manufacturing Equipment 397,230 355,016 Medical Equipment 776,392 783,782 Leasehold Improvements 26,902 21,603 Total 1,234,629 1,191,797 Accumulated depreciation (239,650 ) (116,555 ) Net $ 994,979 $ 1,075,242 Depreciation expense was $124,388 and $89,779 for the years ended December 31, 2020 and 2019, respectively.

Intangible Assets, Net

Intangible Assets, Net	12 Months Ended
	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets, Net	NOTE 7 – Intangible Assets, Net Intangible assets, net, consist of: December 31, 2020 December 31, 2019 Video conferencing software acquired by Prosperity in December 2009 $ 30,000 $ 30,000 Enterprise and audit software acquired by Prosperity in April 2008 20,000 20,000 Patent costs incurred by WRAP 6,880 6,880 Hemp license and technology - 1,000,000 CBD technology 482,000 482,000 Platform account contract 131,812 - Hemp processing use 85,200 - Other 3,548 3,548 Total 759,440 1,542,428 Accumulated amortization and Impairment (236,431 ) (202,521 ) Net $ 523,009 $ 1,339,907 Estimated future amortization expense are as follows: December 31, Amount 2021 $ 120,513 2022 65,591 2023 65,591 2025 65,591 2026 55,449 Thereafter 150,274 Total $ 523,009 The CBD related technology were purchased from Hudilab, Inc. (“HUDI”) and Seven Chakras, LLC (“Seven Chakras”) during the three months ended March 31, 2019. On January 14, 2019, the Company and PHP (collectively, the “buyer”) entered into a License and Acquisition Agreement (the “LAA”) with HUDI. Pursuant to the LAA, HUDI will sell the technology owned by it to the buyer in exchange for 25,000 shares of CANB common stock. On January 14, 2019, the shares were issued to the owner of HUDI and valued at $382,500. On January 31, 2019, PHP entered into an Asset Purchase Agreement (the “Chakras Agreement”) with Seven Chakras. Pursuant to the Chakras Agreement, PHP purchased the rights and title to (i) Seven Chakras’ proprietary formulas, methods, trade secrets, and know-how related to the production of Seven Chakras’ products containing cannabidiol (CBD), (ii) Seven Chakras’ tradename, domain name, and social media sites, and (iii) other assets of Seven Chakras including but not limited to raw materials, equipment, packaging and labeling materials, mailing lists, and marketing materials. On February 20, 2019, the Company issued 3,333 shares of CANB common stock valued at $49,500 to owners of Seven Chakras as additional consideration, along with the $50,000 cash payments, pursuant to the Chakras Agreement. The hemp related license and technology was purchased from Shi Farms during the three months ended September 30, 2019. Hemp Depot has remained dormant since the Shi Farms deal was consummated and no activity is contemplated. As a result, the Company has written off the remaining intangible asset from Shi Farms. The Company subsequently acquired Green Grow Farms, also a NY State Hemp License holder and intends to contract with farmers in New York to grow hemp under a controlled program of specific strains, cultured feminized seeds, proven technology, and access to processing for their crop. Grow Farms Inc. intends to amalgamate the cultivated off-take from the farmers, combine and fill “super-sacks” for shipping to a processing facility to produce high-grade isolate or distillate for use in Can B̅’s manufacturing facility in Lacey WA, if and when it becomes financially prudent for the Company to do so. The hemp processing use agreement with Mediiusa Group, Inc. was entered during the three months ended June 30, 2020. On June 23, 2020, the Company issued 50,000 shares of CANB common stock valued at $69,375. On December 12, 2020, the company issued 50,000 shares of CANB common stock valued at $15,825. Mediiusa Group, Inc. currently holds a valid Industrial Hemp Processor Registration in full force and effect with the State of New York and is authorized to process Hemp, and has granted a five year agreement to processing of Hemp for oil, isolate, or crude for further use by the Company and/or for sale by the Company. During the Term of this Agreement, Mediiusa Group, Inc. agrees to allow CANB to process any and all of the subject Hemp under and/or in connection with the agreement under their above-mentioned Registration. The platform account contract with SRAX, Inc. was entered during the three months ended June 30, 2020. On June 22, 2020, the Company issued 185,000 shares of CANB common stock valued at $131,812. The Platform Account is the SRAX Investors Relations platform to grant access to potential investors and customers via the SRAX website for one year. SRAX grants Can B Corp a non-exclusive, non-transferable and non- sublicensable right to access and use the Platform during the Term, solely by the Authorized Users for User’s own internal business purposes, and in accordance with the terms and conditions of this Agreement. Company reserves all rights in or to the Platform not expressly granted to User in the Agreement. Can B will have previously unattainable access to its customer base for improved investor communication and development of sales opportunities of the Company’s products. The other intangible assets relate to the document management and email marketing divisions. Since December 31, 2017, the Company do not expect any future positive cash flow from these divisions. Accordingly, the net carrying value of these intangible assets was reduced to $0.

Notes and Loans Payable

Notes and Loans Payable	12 Months Ended
	Dec. 31, 2020
Debt Disclosure [Abstract]
Notes and Loans Payable	NOTE 8 – Notes and Loans Payable Notes and loans payable consist of: December 31, December 31, Loan payable to Pasquale Ferro, interest at 12% per annum, due December 2020. $ 224,000 $ 30,000 Note payable to brother of Marco Alfonsi, Chief Executive Officer of the Company, interest at 10% per annum, due August 22, 2016. - 5,000 Note payable to Arena Special Opportunities Partners I, LP, due September 10, 2021. 2,675,239 - Note payable to Arena Special Opportunities Fund, LP, due September 10, 2021. 102,539 - Note payable to U.S. Small Business Administration (PPP), interest at 1% per annum. The note matures in January 2023. Payments are deferred for ten months after the end of the covered period. The Note has been submitted to the SBA for forgiveness withing the bank guidelines. 194,940 - Total Notes and Loan Payable 3,196,718 35,000 Less: Unamortized Finance Cost (1,174,247 ) - Less: Current Portion (1,827,531 ) (35,000 ) Long-term Portion $ 194,940 $ -

Preferred Stock

Preferred Stock	12 Months Ended
	Dec. 31, 2020
Equity [Abstract]
Preferred Stock	NOTE 9 – Preferred Stock Each share of Series A Preferred Stock is convertible into 33,334 shares of CANB common stock and is entitled to 66,666 votes. All Preferred Shares shall rank senior to all shares of Common Stock of the Company with respect to liquidation preferences and shall rank pari passu pari passu Each share of Series B Preferred Stock has the first preference to dividends, distributions and payments upon liquidation, dissolution and winding-up of the Company, and is entitled to an accrued cumulative but not compounding dividend at the rate of 5% per annum whether or not declared. After six months of the issuance date, such share and any accrued but unpaid dividends can be converted into common stock at the conversion price which is the lower of (i) $0.0101; or (ii) the lower of the dollar volume weighted average price of CANB common stock on the trading day prior to the conversion day or the dollar volume weighted average price of CANB common stock on the conversion day. The shares of Series B Preferred Stock have no voting rights. Each share of Series C Preferred Stock has preference to payment of dividends, if and when declared by the Company, compared to shares of our common stock. Each Preferred Series C share is convertible into 25,000 shares of common stock. The shares of Series C Preferred Stock have voting rights as if fully converted. Each share of Series D Preferred Stock has 10,000 shares of voting rights only pari passu to common shares voting with no conversion rights and no equity participation. The Company can redeem Series D Preferred Stock at any time for par value. On January 28, 2019, the Company issued 33,333 shares of CANB common stock to a consultant of the Company in exchange for the retirement of 1 share of CANB Series A Preferred Stock. From February 21, 2019 to March 12, 2019, the Company issued aggregately 67,405 shares of CANB common stock to RedDiamond in exchange for the retirement of 157,105 shares of CANB Series B Preferred Stock. On May 28, 2019, the Company issued 3 shares of CANB Series A Preferred Stock to Stanley L. Teeple pursuant to the employment agreement with him. The fair value of the issuance totaled $1,203,000 and will be amortized over the vesting period of four years. On April 26, 2019, the Company issued 6,436 shares of CANB common stock to RedDiamond in exchange for the retirement of 15,000 shares of CANB Series B Preferred Stock. On May 1, 2019, the Company issued 8,581 shares of CANB common stock to RedDiamond in exchange for the retirement of 20,000 shares of CANB Series B Preferred Stock. On May 9, 2019, the Company issued 23,710 shares of CANB common stock to RedDiamond in exchange for the retirement of 55,263 shares of CANB Series B Preferred Stock. On June 7, 2019, the Company issued 10,726 shares of CANB common stock to RedDiamond in exchange for the retirement of 25,000 shares of CANB Series B Preferred Stock. On August 13, 2019, the Company issued 97,607 shares of CANB common stock to RedDiamond in exchange for the retirement of 227,590 shares of CANB Series B Preferred Stock. On December 16, 2019, the Company issued 35,666 shares of CANB common stock to RedDiamond as agreed for the early retirement of CANB Series B Preferred Stock converted in August 2019. From January 1, 2021 through March 25, 2021, the Company issued 1,950 shares of CANB Series Preferred D Stock to officers of the Company. In March 2021, the Company issued 50 Preferred C shares each to Marco Alfonsi, Stanley Teeple, and Pasquale Ferro for services rendered. Each Preferred C was immediately issuable as common at 25 thousand to one so the total issuance was 1,250,000 common shares for each recipient.

Common Stock

Common Stock	12 Months Ended
	Dec. 31, 2020
Equity [Abstract]
Common Stock	NOTE 10 – Common Stock From January 4, 2019 to March 27, 2019, the Company issued aggregately 138,107 shares of CANB common stock to multiple investors pursuant to relative Stock Purchase Agreements dated on various dates, in exchange for total proceeds of $1,196,100. On January 14, 2019, the Company issued 25,000 shares of CANB common stock to Hudilab, Inc. (“HUDI”), pursuant to a License and Acquisition Agreement for purchase of the technology owned by HUDI. From January 18, 2019 to March 17, 2019, the Company issued aggregately 82,000 shares of CANB common stock to multiple consultants for services rendered. From January 19, 2019 to March 27, 2019, the Company issued aggregately 3,893 shares of CANB common stock to employee and officers of the Company pursuant to employee agreement and in satisfaction of accrued compensation for the quarter ended March 31, 2019. On February 5, 2019, the Company issued 6,667 shares to the owner of TZ Wholesale LLC, pursuant to a Memorandum of Understanding (the “MOU”) dated November 9, 2018. On February 20, 2019, the Company issued 3,333 shares of CANB common stock to owners of Seven Chakras pursuant to the Chakras Agreement dated January 31, 2019. From April 1, 2019 through June 30, 2019 the Company issued an aggregate of 51,706 shares of CANB Common Stock to multiple consultants for services rendered. From April 1, 2019 through June 30, 2019, the Company issued an aggregate of 13,916 shares of CANB Common Stock to members of the Advisory Board, Medical Advisory Board, and Sports Advisory Board for services rendered. From April 1, 2019 through June 30, 2019, the Company issued an aggregate of 4,615 shares of Common Stock under the terms of executive employment agreements. From April 1, 2019 through June 30, 2019, the Company issued an aggregate of 86,207 shares of CANB shares under the terms of the Stock Purchase Agreements for total proceeds of $750,000. From July 1, 2019 through September 30, 2019, the Company issued an aggregate of 18,061 shares of CANB Common Stock to multiple consultants for services rendered. From July 1, 2019 through September 30, 2019, the Company issued an aggregate of 18,333 shares of CANB Common Stock to members of the Advisory Board, Medical Advisory Board, and Sports Advisory Board for services rendered. From July 1, 2019 through September 30, 2019, the Company issued an aggregate of 16,000 shares of Common Stock under the terms of executive employment agreements. From July 1, 2019 through September 30, 2019, the Company issued an aggregate of 155,241 shares of CANB shares under the terms of the Stock Purchase Agreements for total proceeds of $1,350,600. From July 1, 2019 through September 30, 2019, the Company issued an aggregate of 40,247 shares of CANB shares under the terms of the Joint Venture Agreement. From October 1, 2019 through December 31, 2019, the Company issued an aggregate of 122,258 shares of CANB Common Stock to multiple consultants for services rendered. From October 1, 2019 through December 31, 2019, the Company issued an aggregate of 14,167 shares of CANB Common Stock to members of the Advisory Board, Medical Advisory Board, and Sports Advisory Board for services rendered. From October 1, 2019 through December 31, 2019, the Company issued an aggregate of 5,000 shares of Common Stock under the terms of executive employment agreements. From October 1, 2019 through December 31, 2019, the Company issued an aggregate of 125,000 shares of CANB Common Stock under the terms of an inventory purchase agreement for total proceeds of $487,500. From January 1, 2020 through March 31, 2020, the Company issued an aggregate of 27,500 shares of CANB Common Stock to multiple consultants for services rendered. From January 1, 2020 through March 31, 2020, the Company issued an aggregate of 31,335 shares of CANB Common Stock to members of the Advisory Board, Medical Advisory Board, and Sports Advisory Board for services rendered. From January 1, 2020 through March 31, 2020, the Company issued an aggregate of 20,000 shares of CANB Common Stock to First Fire Global Opportunities Fund, LLC for a commitment fee pursuant to a junior convertible promissory note purchase agreement. From January 1, 2020 through March 31, 2020, the Company issued an aggregate of 99,508 shares of CANB Common Stock to FirstFire Global Opportunities Fund, LLC for returnable shares pursuant to a junior convertible promissory note purchase agreement. From April 1, 2020 through June 30, 2020, the Company issued an aggregate of 111,734 shares of CANB Common Stock to multiple consultants for services rendered. From April 1, 2020 through June 30, 2020, the Company issued an aggregate of 20,319 shares of CANB Common Stock to members of the Advisory Board, Medical Advisory Board, and Sports Advisory Board for services rendered. From April 1, 2020 through June 30, 2020, the Company issued an aggregate of 30,000 shares of CANB Common Stock to an employee for services rendered. From April 1, 2020 through June 30, 2020, the Company issued an aggregate of 185,000 shares of CANB Common Stock to SRAX, Inc. according to a platform access agreement. From April 1, 2020 through June 30, 2020, the Company issued an aggregate of 50,000 shares of CANB Common Stock to Mediiusa Group, Inc. according to a hemp processing use agreement. From April 1, 2020 through June 30, 2020, the Company issued an aggregate of 24,545 shares of CANB Common Stock to Labrys Fund, L.P. for a commitment fee pursuant to a junior convertible promissory note purchase agreement. From April 1, 2020 through June 30, 2020, the Company issued an aggregate of 118,000 shares of CANB Common Stock to Labrys Fund, L.P. for returnable shares pursuant to a junior convertible promissory note purchase agreement. From April 1, 2020 through June 30, 2020, the Company issued an aggregate of 20,000 shares of CANB Common Stock to Eagle Equities, LLC for a commitment fee pursuant to a junior convertible promissory note purchase agreement. From July 1, 2020 through September 30, 2020, the Company issued an aggregate of 145,000 shares of CANB Common Stock to multiple consultants for services rendered. From July 1, 2020 through September 30, 2020, the Company issued an aggregate of 100,000 shares of CANB Common Stock to members of the Advisory Board, Medical Advisory Board, and Sports Advisory Board for services rendered. From July 1, 2020 through September 30, 2020, the Company issued an aggregate of 478,715 shares of CANB Common Stock to members of the Advisory Board, Medical Advisory Board, and Sports Advisory Board for services rendered. From July 1, 2020 through September 30, 2020, the Company received an aggregate of 543,715 shares of CANB Common Stock from an exchange agreement whereby shares of Iconic Brands, Inc. held by the Company were exchanged for shares of stock in the Company held by Iconic Brands, Inc. From July 1, 2020 through September 30, 2020, the Company issued an aggregate of 478,715 shares of CANB Common Stock for the acquisition of inventory. From July 1, 2020 through September 30, 2020, the Company issued an aggregate of 185,000 shares of CANB Common Stock to FirstFire Global Opportunities Fund, LLC pursuant to a junior convertible promissory note purchase agreement. On July 29, 2020, CANB and Iconic Brands (ICNB) completed a share exchange whereby the one million shares of ICNB common stock held by CANB were exchanged for a fair value exchange of five hundred forty three thousand seven hundred fifteen shares of CANB in order to settle a contract valuation true-up with ICNB for the purchase of Green Grow Farms,. Inc. From October 1, 2020 through December 31, 2020, the company issued an aggregate of 435,311 shares of CANB Common Stock to multiple consultants for services rendered. From October 1, 2020 through December 31, 2020, the Company issued an aggregate of 70,000 shares of CANB Common Stock to members of the Advisory Board, Medical Advisory Board, and Sports Advisory Board for services rendered. From October 1, 2020 through December 31, 2020, the Company issued an aggregate of 50,000 shares of Common Stock under the terms of hemp processing use agreement. From October 1, 2020 through December 31, 2020, the Company issued an aggregate of 600,000 shares of Common Stock under the terms of Stock Purchase Agreements for total proceeds of $300,000. From October 1, 2020 through December 31, 2020, the Company issued an aggregate of 193,524 shares of Common Stock to FirstFire Global as agreed for conversion shares related to a note payable. From October 1, 2020 through December 31, 2020, the Company issued an aggregate of 394,304 shares of CANB Common Stock to Arena Special Opportunities Partners I, LP for a commitment fee pursuant to a securities purchase agreement. From October 1, 2020 through December 31, 2020, the Company issued an aggregate of 15,133 shares of CANB Common Stock to Arena Special Opportunities Fund, LP for a commitment fee pursuant to a securities purchase agreement. From January 1, 2021 through March 25, 2021 the Company issued an aggregate of 5,932,000 shares of Common Stock under its Reg A-1 registration currently in effect and an additional 130,750 shares of common stock to various consultants for services. From January 1, 2021 through March 25, 2021 the Company issued an aggregate of 355,057 shares of Common Stock under an asset acquisition agreement with Botanical Biotech. From January 1, 2021 through March 25, 2021 the Company issued an aggregate of 355,250 shares of Common Stock under note conversion agreement. From January 1, 2021 through March 25, 2021 the Company issued an aggregate of 600,000 shares of Common Stock under a note conversion agreement. From January 1, 2021 through March 25, 2021 the Company issued an aggregate of 150 shares of Preferred C shares under multiple employment agreements. The Preferred C shares converted to 3,750,000 shares of Common Stock upon issuance.

Stock Options and Warrants

Stock Options and Warrants	12 Months Ended
	Dec. 31, 2020
Share-based Payment Arrangement [Abstract]
Stock Options and Warrants	NOTE 11 – Stock Options and Warrants A summary of stock options and warrants activity follows: Shares of Common Stock Exercisable Into Stock Options Warrants Total Balance, December 31, 2018 20,167 7,492 27,659 Granted in 2019 56,667 - 56,667 Cancelled in 2019 (167 ) - (167 ) Exercised in 2019 - - - Balance, December 31, 2019 76,667 7,492 84,159 Granted in 2020 1,120,532 3,557,605 4,678,137 Cancelled 2020 - - - Exercised 2020 - - - Balance, December 31, 2020 1,197,199 3,565,097 4,762,296 Issued and outstanding stock options as of December 31, 2020 consist of: Year Number Outstanding Exercise Year of Granted And Exercisable Price Expiration 2018 20,000 $ 0.30 2023 2019 56,667 $ 0.30 2022 2020 1,120,532 $ 0.361 2025 1,197,199 On June 11, 2018, the Company granted 10,000 options of CANB common stock to Carl Dilley, a former director of the Company, in exchange for the retirement of a total of 10,000 shares of CANB common stock from Carl Dilley. The options are exercisable for the purchase of one share of the Registrant’s Common Stock at an exercise price of $0.30 per share. The Options are fully vested and are exercisable as of the Grant Date and all shall expire June 11, 2023. The value of the Stock Options ($84,000) were calculated using the Black Scholes option pricing model and the following assumptions: (i) $8.40 share price, (ii) 5 years term, (iii) 262.00% expected volatility, (iv) 2.80% risk free interest rate and the difference between this value and the fair value of retired shares was expensed in the quarterly period ended June 30, 2018. On October 21, 2018, the Company granted 10,000 options of CANB common stock to Stanley L. Teeple, an officer and Director of the Company. The options are exercisable for the purchase of one share of the Registrant’s Common Stock at an exercise price of $0.30 per share. The Options are fully vested and are exercisable as of the Grant Date and all shall expire October 1, 2023. The values of the Stock Options ($118,200) were calculated using the Black Scholes option pricing model and the following assumptions: (i) $11.82 share price, (ii) 5 years term, (iii) 221.96% expected volatility, (iv) 3.05% risk free interest rate and the fair value of options was expensed in the quarterly period ended December 31, 2018 On September 9, 2019, the Company granted 26,667 options of CANB common stock to Johnny Mack, a former officer of the Company. The options are exercisable for the purchase of one share of the Registrant’s Common Stock at an exercise price of $0.30 per share. The Options are fully vested and are exercisable as of the Grant Date and all shall expire September 9, 2022. The values of the Stock Options ($192,000) were calculated using the Black Scholes option pricing model and the following assumptions: (i) $7.20 share price, (ii) 3 years term, (iii) 463,34% expected volatility, (iv) 1.46% risk free interest rate and the fair value of options was expensed in the quarterly period ended September 30, 2019. On October 15, 2019, the Company granted 10,000 options of CANB common stock each to Frederick Alger Boyer, Jr., Ronald A. Silver and James F. Murphy, directors of the Company. The options are exercisable for the purchase of one share of the Registrant’s Common Stock at an exercise price of $0.30 per share. The Options are fully vested and are exercisable as of the Grant Date and all shall expire October 15, 2022. The values of the Stock Options ($63,000 each) were calculated using the Black Scholes option pricing model and the following assumptions: (i) $6.30 share price, (ii) 3 years term, (iii) 463,34% expected volatility, (iv) 1.60% risk free interest rate and the fair value of options was expensed in the quarterly period ended December 31, 2019. On December 9, 2020, the Company granted 12,500 options of CANB common stock to Ronald A. Silver, a director of the Company. The options are exercisable for the purchase of one share of the Registrant’s Common Stock at an exercise price of $0.50 per share. The Options are fully vested and are exercisable as of the Grant Date and all shall expire December 9, 2025. The values of the Stock Option ($12,500) was calculated using the Black Scholes option pricing model and the following assumptions: (i) $.45 share price, (ii) 5 years term, (iii) 168% expected volatility, (iv) .41% risk free interest rate and the fair value of options was expensed in the quarterly period ended December 31, 2020. On December 29, 2020, the Company granted 277,008 options of CANB common stock each to Stanley Teeple, Pasquale Ferro, Phil Scala and Marco Alfonsi, Officers of the Company. The options are exercisable for the purchase of one share of the Registrant’s Common Stock at an exercise price of $0.36 per share. The Options are fully vested and are exercisable as of the Grant Date and all shall expire December 29, 2025. The values of the Stock Options ($140,997 each) were calculated using the Black Scholes option pricing model and the following assumptions: (i) $.51 share price, (ii) 5 years term, (iii) 168% expected volatility, (iv) .41% risk free interest rate and the fair value of options was expensed in the quarterly period ended December 31, 2020. Issued and outstanding warrants as of December 31, 2020 consist of: Year Number Outstanding Exercise Year of Granted And Exercisable Price Expiration 2010 825 $ 300 2020 2018 6,667 $ 13,034 (a) 2023 2020 3,557,605 $ 1,273,623 2025 Total 3,565,097 (a) 110% of the closing price of the Company’s common stock on the date that the Holder funds the full purchase price of the Note.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 12 – Income Taxes No provisions for income taxes were recorded for the periods presented since the Company incurred net losses in those periods. The provisions for (benefits from) income taxes differ from the amounts determined by applying the U.S. Federal income tax rate of 21% to pretax income (loss) as follows: December 31, 2020 2019 Expected income tax (benefit) at 21% $ (1,200,467 ) $ (1,239,160 ) Non-deductible stock-based compensation 474,428 923,470 Non-deductible stock-based interest 94,853 - Increase in deferred income tax assets valuation allowance 631,186 315,690 Provision for (benefit from) income taxes $ - $ - Deferred income tax assets consist of: December 31, December 31, 2020 2019 Net operating loss carryforward 1,931,355 1,300,168 Valuation allowance (1,931,355 ) (1,300,168 ) Net $ - $ - Based on management’s present assessment, the Company has not yet determined it to be more likely than not that a deferred income tax asset of $1,931,355 attributable to the future utilization of the $9,196,924 net operating loss carryforward as of December 31, 2020 will be realized. Accordingly, the Company has maintained a 100% allowance against the deferred income tax asset in the financial statements at December 31, 2020. The Company will continue to review this valuation allowance and make adjustments as appropriate. The net operating loss carryforward expires in years 2025, 2026, 2027, 2028, 2029, 2030, 2031, 2032, 2033, 2034, 2035, 2036, 2037, 2038, 2039 and 2040 in the amount of $1,369, $518,390, $594,905, $686,775, $159,141, $151,874, $135,096, $166,911, $311,890, $25,511, $338,345, $381,638, $499,288, $716,858, $1,503,282, and $3,005,651, respectively. Current tax laws limit the amount of loss available to be offset against future taxable income when a substantial change in ownership occurs. Therefore, the amount available to offset future taxable income may be limited. The Company’s U.S. Federal and state income tax returns prior to 2016 are closed and management continually evaluates expiring statutes of limitations, audits, proposed settlements, changes in tax law and new authoritative rulings. The statute of limitations on the 2016 tax year returns expired in September 2020. The Company recognizes interest and penalties associated with uncertain tax positions as part of the income tax provision and would include accrued interest and penalties with the related tax liability in the consolidated balance sheets. There were no interest or penalties paid during 2020 and 2019.

Segment Information

Segment Information	12 Months Ended
	Dec. 31, 2020
Segment Reporting [Abstract]
Segment Information	NOTE 13 – Segment Information The Company has one reportable segment: Durable Equipment Products. The accounting policies of the segment described above are the same as those described in Summary of Significant Accounting Policies in Note 3. The Company evaluates the performance of the Durable Equipment Products segment based on income (loss) before income taxes, which includes interest income. Durable Equipment Products Three months ended December 31, 2020 Revenue from external customers 367,673 Revenue from other segments - Segment profit 276,226 Segment assets 2,603,379 Twelve months ended December 31, 2020 Revenue from external customers 1,176,220 Revenue from other segments - Segment profit 691,482 Segment assets 2,603,379 Three Months Ended December 31, 2020 Twelve Months Ended December 31, 2020 Total profit for reportable segment $ 278,719 $ 694,828 Other income (expense) - net (2,493 ) (3,346 ) Income before income taxes $ 276,226 $ 691,482

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE 14 – Commitments and Contingencies Employment Agreements On December 28, 2020, the Company entered into new three-year Employment Agreements with CEO Marco Alfonsi, CFO Stanley Teeple, and Pure Health Products LLC Pasquale Ferro . Under these agreements, the are to receive a i) base salary of fifteen thousand dollars ($15,000.00) per month, ii) is eligible to receive cash and or stock bonuses, iii) shall receive a stock bonus in accordance with the Company’s Incentive Stock Option Plan (“ISOP”) in an amount of one-hundred thousand dollars ($100,000) per year of the Agreement, iv) 200 shares of the Company’s Series C Preferred stock, v) usual and customary benefits including expense reimbursement, health and life insurance plan reimbursements and allowances. Phil Scala. Interim COO also received a similar agreement with a base compensation of fifty-two thousand annually, $100,000 in ISO, and 20 Preferred C shares. The foregoing agreements have replaced the agreements described below. On October 3, 2017, the Company executed an Executive Employment Agreement with Marco Alfonsi (“Alfonsi”) for Alfonsi to serve as the Company’s chief executive officer and interim chief financial officer and secretary for cash compensation of $10,000 per month. Pursuant to the agreement, the Company issued a share of CANB Series A Preferred Stock to Alfonsi on October 4, 2017. Alfonsi may terminate his employment upon 30 days written notice to the Company. The Company may terminate Alfonsi’s employment upon written notice to Alfonsi by a vote of the Board of Directors. At October 21, 2018, this former agreement was terminated due to the execution of a new Employment Agreement with Marco Alfonsi for Alfonsi to serve as the Company’s chief executive officer and chairman of the board for cash compensation of $15,000 per month. Pursuant to the new agreement, three of the eight previously issued shares of CANB Series A Preferred Stock were returned to the Company and converted into 30,000,000 common shares. Alfonsi may terminate his employment upon 30 days written notice to the Company. The new agreement has an initial term of four years and can be terminated upon the resignation or death of Mr. Alfonsi, and also can be terminated by the Company due to the failure or neglect of Mr. Alfonsi to perform his duties, or due to the misconduct of Mr. Alfonsi in connection with the performance. On February 12, 2018, the Company executed an Executive Service Agreement (“Posel Agreement”) with David Posel. The Posel Agreement provides that Mr. Posel services as the Company’s Chief Operating Officer for a term of 4 years. The Posel Agreement also provides for compensation to Mr. Posel of $5,000 cash per month and the issuance of 1 share of Series A Preferred Stock at the inception of the Posel Agreement. The Posel Agreement can be terminated upon the resignation or death of Mr. Posel, and also can be terminated by the Company due to the failure or neglect of Mr. Posel to perform his duties, or due to the misconduct of Mr. Posel in connection with the performance. On February 12, 2018, 1 share of CANB Series A Preferred Stock were issued to Mr. Posel. Since execution of the Posel Agreement, Mr. Posel has been re-assigned to COO for Pure Health Products, the Company’s subsidiary. On February 16, 2018, the Company executed an Executive Service Agreement (“Holtmeyer Agreement”) with Andrew W. Holtmeyer. The Holtmeyer Agreement provides that Mr. Holtmeyer serves as the Company’s Executive Vice President Business for a term of 3 years. The Holtmeyer Agreement also provides for compensation to Mr. Holtmeyer of $10,000 cash per month and the issuance of 3, 2 and 1 share of Series A Preferred Stock at the beginning of each year. The Holtmeyer Agreement can be terminated upon the resignation or death of Mr. Holtmeyer, and also can be terminated by the Company due to the failure or neglect of Mr. Holtmeyer to perform his duties, or due to the misconduct of Mr. Holtmeyer in connection with the performance. At December 29, 2018, this Holtmeyer Agreement was terminated due to the execution of a new Employment Agreement with Andrew W Holtmeyer. The second agreement provides that Mr. Holtmeyer serves as the Company’s Executive Vice President Business for a term of 4 years. The second agreement also provides for compensation to Mr. Holtmeyer of $15,000 cash per month and the issuance of 829 shares of common stock upon signing of the agreement. Effective April 1, 2020, Mr. Holtmeyer’s compensation was changed to a straight commission on sales and collection based upon his efforts in lieu of any base compensation. He also will receive no further Company benefits but does retain his previously issued five shares of Series Preferred A Stock. On October 15, 2018, the Company executed an Employment Agreement (“Teeple Agreement”) with Stanley L. Teeple. The Teeple Agreement provides that Mr. Teeple services as the Company’s Chief Financial Officer and Secretary for a term of 4 years. The Teeple Agreement also provides for compensation to Mr. Teeple of $15,000 cash per month and the issuance of 1 share of Series A Preferred Stock proportionately vesting over four years beginning December 31, 2018 upon execution of the Teeple Agreement. The Teeple Agreement can be terminated upon the resignation or death of Mr. Teeple, and also can be terminated by the Company due to the failure or neglect of Mr. Teeple to perform his duties, or due to the misconduct of Mr. Teeple in connection with the performance. In May 2019 Mr. Teeple was granted an additional 3 shares of Series A Preferred. On December 28, 2018, the Company executed an Employment Agreement (“Ferro Agreement”) with Pasquale Ferro for Mr. Ferro to serve as Pure Health Products’ president for cash compensation of $15,000 per month and the total issuance of 5 share of Series A Preferred Stock proportionately vesting at the beginning of each year for a term of 4 years. Mr. Ferro may terminate his employment upon 30 days written notice to the Company. The Ferro Agreement has an initial term of four years and can be terminated upon the resignation or death of Mr. Ferro, and also can be terminated by the Company due to the failure or neglect of Mr. Ferro to perform his duties, or due to the misconduct of Mr. Ferro in connection with the performance. Effective September 6, 2019 (the “Effective Date”), Can B̅ Corp. (the “Company” or “CANB”) approved the appointment of Johnny J. Mack (“Mack”) as its President and Chief Operating Officer. Mack had been serving as the Company’s interim COO. The Company and Mack have entered into a new Employee Services Agreement (the “Mack Agreement”) to memorialize the terms of the foregoing. In consideration for Mack’s services, Mack would (i) receive a base salary of $15,000 per month, subject to increase after each yearly anniversary of the Agreement, (ii) be eligible to receive annual cash or stock bonuses, (iii) be entitled to four weeks’ vacation time and five paid days for illness in accordance with the Company’s policies, and (iv) receive a total of 106,667 options (“Mack Options”) to purchase shares of the Company’s common stock, with 26,667 Mack Options vesting on the effective date and additional tranches of 26,667 Mack Options vesting on each of the first, second, and third anniversaries of the Effective Date, assuming Mack’s continued employment. Each Option is exercisable at a price of $0.30 per share. The Company also agreed to hold harmless and indemnify Mack as authorized or permitted by law and the Company’s governing documents, as the same may be amended from time to time, except for acts constituting negligence or willful misconduct by Mack. The Company agreed to pay Mack a severance in the event the Mack Agreement is terminated by the Company without cause or by Mack for “good reason” or by reason of Mack’s death or disability. On October 4, 2019 Mack resigned from all of his officer and director positions and the Company settled his termination for payment of all accrued expenses, payout of all accrued time and base compensation of $13,315 and retention of his already earned 26,667 options. Mr. Mack has left the Company. In addition, on October 10 th Consulting Agreements On July 15, 2020, we engaged an advisor to provide consulting services under an Investor Relations and Advisory Agreement (the “Advisory Agreement”). Pursuant to the Advisory Agreement, we agreed to pay the Consulting Firm a restricted common stock monthly fee of $5,000 per month for the initial 3 months., $6,250 per month for months 4-6., $7,500 per month for month 7 and after. At CANB’s option, the monthly fee may be payable in part or in whole in cash. Monthly Fee, such amount shall be paid via issuance of restricted common shares of CANB. The shares are to be issued in the name of Tysadco Partners. The number of common shares earned each month shall be calculated and issued on a quarterly basis prior to each 90-day period and based on the value at the closing price on the last day of the preceding period. All common shares earned by the Consultant pursuant to this Agreement shall be issued by CANB on a quarterly basis. CT shall not have registration rights, and the shares may be sold subject to Rule 144. On December 8, 2019, the Company executed a Consulting Agreement with Seacore Capital, Inc. (“Seacore”) for Seacore to serve as the Company’s consultant for stock compensation of a total of 8,333 restricted shares each quarter from 4 th rd Lease Agreements On September 11, 2015, the Company executed a lease agreement with an unrelated third party for office space in Hicksville, New York for a term of 37 months. The lease provides for monthly rentals of $2,922 for lease year 1, $3,009 for lease year 2, and $3,100 for lease year 3. The lease also provides for additional rent based on increases in base year operating expenses and real estate taxes. On August 6, 2018, the Company renewed the lease agreement for a term of 36 months starting November 1, 2018. The lease provides for monthly rentals of $3,193 for lease year 1, $3,289 for lease year 2, and $3,388 for lease year 3. In October 2019, the Company modified and extended the lease agreement for a term of 30 months starting November 1, 2019. The lease provides for monthly rentals of $3,807.05 for year 1 and $3,921.26 for the remaining eighteen months. The original $100,681 right-of-use asset and $90,591 lease liability was adjusted to $103,260 with the modification. The Company leases office space in numerous medical facilities offices under month-to-month agreements. Rent expense for the years ended December 31, 2020 and 202019 was $234,790 and $246,968, respectively. At December 31, 2020, the future minimum lease payments under non-cancellable operating leases were: Year ended December 31, 2021 47,055 Year ended December 31, 2022 15,685 Total $ 62,740 The lease liability of $43,506 at December 31, 2020 as presented in the Consolidated Balance Sheet represents the discounted (at our 10% estimated incremental borrowing rate) value of the future lease payments of $62,740 at December 31, 2020. Major Customers For the twelve months ended December 31, 2020, there were no customers that accounted for more than 10% of total revenues. For the twelve months ended December 31, 2019, there were no customers that accounted for more than 10% of total revenues.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2020
Related Party Transactions [Abstract]
Related Party Transactions	NOTE 15 – Related Party Transactions LI Accounting Associates, LLC (LIA), an entity controlled by a relative of the Managing Member PHP, is a vendor of CANB. At December 31, 2020, CANB did not have an account payable due to LIA. For the twelve months ended December 31, 2020, CANB had expenses to LIA of $64,400. During the twelve months ended December 31, 2020, we had products and service sales to related parties totaling $0.

Prior Period Adjustment

Prior Period Adjustment	12 Months Ended
	Dec. 31, 2020
Accounting Changes and Error Corrections [Abstract]
Prior Period Adjustment	NOTE 16 – Prior Period Adjustment The accompanying consolidated financial statements of the Company have been restated to correct an error made in the prior year. The error relates to an understatement of intangible assets by $283,345 and an understatement of stock- based compensation of $1,308,290. Retained earnings as of December 31, 2020 has been adjusted for the effect of the restatement on the prior year.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2020
Subsequent Events [Abstract]
Subsequent Events	NOTE 17 – Subsequent Events In accordance with FASB ASC 855, Subsequent Events, the Company has evaluated subsequent events through March 25, 2021, the date on which these consolidated financial statements were available to be issued. There were material subsequent events that required recognition or additional disclosure in these consolidated financial statements as follows: On January 30, 2020, the World Health Organization (“WHO”) announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China (the “COVID-19 outbreak”) and the risks to the international community as the virus spreads globally beyond its point of origin. In March 2020, the WHO classified the COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally. The full impact of the COVID-19 outbreak continues to evolve as of the date of this report. As such, it is uncertain as to the full magnitude that the pandemic will have on our financial condition, liquidity, and future results of operations. Management is actively monitoring the impact of the global situation on our financial condition, liquidity, operations, suppliers, industry, and workforce. Given the daily evolution of the COVID-19 outbreak and the global responses to curb its spread, we are not able to estimate the effects of the COVID-19 outbreak on our results of operations, financial condition, or liquidity for the year ended December 31, 2021. On February 8, 2021, the Company’s Board of Directors approved the designation of the Series D Preferred Shares and the number of shares constituting such series, and the rights, powers, preferences, privileges and restrictions relating to such series. On March 27, 2021, the Company filed an amendment to its articles of incorporation to authorize 4,000 shares of a new Series D Preferred Stock with a par value of $0.001 each. All Series D Preferred Shares shall rank senior to all shares of Common Stock of the Company with respect to liquidation preferences and shall rank pari passu On February 22, 2021, the Company entered into a material definitive agreement with its wholly owned subsidiary, Radical Tactical, LLC, a Nevada limited liability company and Imbibe Health Solutions, LLC, a Delaware limited liability company (“Imbibe”), pursuant to which Imbibe agreed to sell certain of its assets to Radical Tactical. The assets to be purchased (“Assets”) include the intellectual property rights, including trademarks, logos, know how, formulations, productions procedures, copyrights, social media accounts, domain names and marketing materials relating to its branded products containing CBD, including a muscle and joint salve, unscented fizzy bath soak, CALM massage oil, Me x 3 Metabolic Energy (energy and dietary supplement), and Muscle, Joints & Back CBD Cryo Gel; inventory; and goodwill. In exchange for the Assets, the Company has agreed to pay Imbibe Sixty-Five Thousand Dollars ($65,000) in the form of shares of common stock of the Company (with standard restricted legend, the “Shares”) at a price per share equal to the average price of the common stock of the Company during the ten (10) consecutive trading days immediately preceding the closing. On March 11, 2021, Company entered into an Asset Acquisition Agreement, which was fully executed on March 17, 2021, with multiple sellers (each, a “Seller” and, collectively, the “Sellers”), pursuant to which the Sellers agreed to sell certain assets to Company, and to transfer such assets to Botanical Biotech, LLC, a newly-formed, wholly-owned subsidiary of the Company (“Transferee” or “BB”). The assets purchased (“BB Assets”) include certain materials and manufacturing equipment; goodwill associated therewith; and marketing or promotional designs, brochures, advertisements, concepts, literature, books, media rights, rights against any other person or entity in respect of any of the foregoing and all other promotional properties, in each case primarily used, developed or acquired by the Sellers for use in connection with the ownership and operation of the BB Assets. In exchange for the BB Assets, the Company originally agreed to pay the Sellers the fair value of the BB Assets, as determined by a neutral third-party appraiser selected by the Company and Sellers. Notwithstanding the foregoing, the parties have agreed that, in lieu of engaging a third-party evaluator, the Company will pay the Seller a maximum of $355,056.78, payable half in the form of cash or cash equivalent and half in the form of restricted shares of common stock of the Company (the “Shares”) at a price per Share equal to the average closing price of the common stock of the Company during the ten (10) consecutive trading days immediately preceding the closing. The Company has agreed to indemnify the Sellers for certain breaches of covenants, representations and warranties and for claims relating to the BB Assets following closing. The Board of Directors had previously designed a Preferred Series C share designation and included that issuance in the Employment Agreements of CEO Marco Alfonsi, CFO, Stanley L. Teeple, and Pure Health Products LLC President Pasquale Ferro in the amount of 200 shares each. Previously the Board had released the issuance of 100 of those shares. The Company released the remaining 100 shares granted under those agreements on March 23, 2021. Out of the 200 each authorized, 50 have been issued to each employee. n January 1, 2021, the Company issued a convertible promissory note to KORR Acquisition Group, Inc. in the principal amount of $175,000 for consulting services provided. The note had a maturity of one year and accrued interest at a rate of 6% per annum. On or around March 26, the Company paid the note in full. KORR used the proceeds from the Note and re-invested it through the Company’s Regulation A offering.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Principles of Consolidation	(a) Principles of Consolidation The consolidated financial statements include the accounts of CANB and its wholly-owned subsidiaries, Pure Health Products, Duramed, Prosperity Radical Tactical and Green Grow Farms. All intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates	(b) Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.
Fair Value of Financial Instruments	(c) Fair Value of Financial Instruments The Company’s financial instruments consist of cash and cash equivalents, accounts receivable, notes receivable, notes and loans payable, accounts payable, and accrued expenses payable. Except for the noncurrent note receivable, the fair value of these financial instruments approximate their carrying amounts reported in the balance sheets due to the short term maturity of these instruments. Based on comparable instruments with similar terms, the fair value of the noncurrent note receivable approximates its carrying value. Pursuant to ASC 820, Fair Value Measurements and Disclosures, an entity is required to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value: Level 1 - applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. Level 2 - applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data. Level 3 - applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.
Cash and Cash Equivalents	(d) Cash and Cash Equivalents The Company considers all liquid investments purchased with a maturity of three months or less to be cash equivalents.
Accounts Receivable	(e) Accounts receivable Accounts receivable are presented in the balance sheet net of the allowance for doubtful accounts. Accounts receivable are written off when they are determined to be uncollectible. The allowance for doubtful accounts is estimated based on the Company’s historical losses, the existing economic conditions in the industry, and the financial stability of its customers. Bad debt expense was $270,919 and $0 for the periods ended December 31, 2020 and 2019.
Inventory	(f) Inventory Inventories consist of raw materials and finished goods and are stated at the lower of cost or net realizable value. Cost is principally determined using the first-in, first-out (FIFO) method.
Prepaid Expenses	(g) Prepaid expenses Prepaid expenses include stock-based officer, employee and consulting compensation of $1,216,531 and $2,459,830 at December 31, 2020 and 2019, respectively. The Company’s policy is to record stock-based compensation as prepaids and expense over the term of employment and consulting agreements.
Property and Equipment, Net	(h) Property and Equipment, Net Property and equipment, net, is stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the respective assets. Maintenance and repairs are charged to operations as incurred.
Intangible Assets, Net	(i) Intangible Assets, Net Intangible assets, net, are stated at cost less accumulated amortization. Amortization is calculated using the straight-line method over the estimated economic lives of the respective assets.
Goodwill	(j) Goodwill The Company does not amortize goodwill, but instead tests for impairment at least annually. When conducting the annual impairment test for goodwill, the Company compares the estimated fair value of a reporting unit containing goodwill to its carrying value. If the estimated fair value of the reporting unit is determined to be less than its carrying value, goodwill is reduced, and an impairment loss is recorded.
Long-lived Assets	(k) Long-lived Assets The Company reviews long-lived assets held and used, intangible assets with finite useful lives and assets held for sale for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If an evaluation of recoverability is required, the estimated undiscounted future cash flows associated with the asset is compared to the asset’s carrying amount to determine if a write-down is required. If the undiscounted cash flows are less than the carrying amount, an impairment loss is recorded to the extent that the carrying amount exceeds the fair value.
Revenue Recognition	(l) Revenue Recognition The Company recognizes revenue in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers, which requires that five basic steps be followed to recognize revenue: (1) a legally enforceable contract that meets criterial standards as to composition and substance is identified; (2) performance obligations relating to provision of goods or services to the customer are identified; (3) the transaction price, with consideration given to any variable, noncash, or other relevant consideration, is determined; (4) the transaction price is allocated to the performance obligations; and (5) revenue is recognized when control of goods or services is transferred to the customer with consideration given, whether that control happens over time or not. Determination of criteria (3) and (4) are based on our management’s judgments regarding the fixed nature of the selling prices of the products and services delivered and the collectability of those amounts. Private Label Customers are wholesale distributors of the Company’s product, under their own wholesale private label brand. The products are made to Company specifications and shipped directly to the wholesaler. The pricing is predicated upon a volume discount negotiated at the time of the placement of the orders. Product is produced and labeled in the Washington manufacturing facility and shipped directly to the Private Label customer who re-distributes to their retail and other customers. The products are fully paid when shipped. Revenue from product sales is recognized when an order has been obtained, the price is fixed and determinable, the product is shipped, title has transferred, and collectability is reasonably assured. The Company’s Duramed Division provides a sam® Pro 2.0 medical device to patients through a doctor program whereby the physician evaluates the patients’ needs for medical necessity, and if determined that the device use would be beneficial, writes a prescription for the patient who signs a rental form, for a 35 day cycle for the unit, that is submitted to Duramed who bills the appropriate insurance company. The insurance company pays the invoice, or a negotiated amount via arbitration, and that revenue is reported as revenue when invoiced to the insurance carrier. The collected amount is reconciled with the invoice amount on a daily basis.
Cost of Product Sales	(m) Cost of Product Sales The cost of product sale is the total cost incurred to obtain a sale and the cost of the goods sold, and the Company’s policy is to recognize it in the same manner as, and in conjunction with, revenue recognition. Cost of product sale primarily consisted of the costs directly attributable to revenue recognized and includes expenses related to the production, packaging and labeling of our CBD products.
Stock-Based Compensation	(n) Stock-Based Compensation Stock-based compensation is accounted for at fair value in accordance with Accounting Standards Codification (“ASC”) Topic 718, “Compensation – Stock Compensation” (“ASC718”) and ASC 505-50, “Equity – Based Payments to Non-Employees.” In addition to requiring supplemental disclosures, ASC 718 addresses the accounting for share-based payment transactions in which a company receives goods or services in exchange for (a) equity instruments of the company or (b) liabilities that are based on the fair value of the company’s equity instruments or that may be settled by the issuance of such equity instruments. ASC 718 focuses primarily on accounting for transactions in which a company obtains employee services in share-based payment transactions. In accordance with ASC 505-50, the Company determines the fair value of the stock-based payment as either the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. If the fair value of the equity instruments issued is used, it is measured using the stock price and other measurement assumptions as of the earlier of either (1) the date at which a commitment for performance by the counterparty to earn the equity instrument is reached, or (2) the date at which the counterparty’s performance is complete. Options and warrants The fair value of stock options and warrants is estimated on the measurement date using the Black-Scholes model with the following assumptions, which are determined at the beginning of each year and utilized in all calculations for that year: Risk-Free Interest Rate. We utilized the U.S. Treasury yield curve in effect at the time of grant with a term consistent with the expected term of our awards. Expected Volatility. We calculate the expected volatility based on a volatility index of peer companies as we did not have sufficient historical market information to estimate the volatility of our own stock. Dividend Yield. We have not declared a dividend on its common stock since its inception and have no intentions of declaring a dividend in the foreseeable future and therefore used a dividend yield of zero. Expected Term. The expected term of options granted represents the period of time that options are expected to be outstanding. We estimated the expected term of stock options by using the simplified method. For warrants, the expected term represents the actual term of the warrant. Forfeitures. Estimates of option forfeitures are based on our experience. We will adjust our estimate of forfeitures over the requisite service period based on the extent to which actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures will be recognized through a cumulative catch-up adjustment in the period of change and will also impact the amount of compensation expense to be recognized in future periods.
Advertising	(o) Advertising Advertising costs are expensed as incurred and amounted to $519,922 and $333,441 for the years ended December 31, 2020 and 2019, respectively.
Research and Development	(p) Research and Development Research and development costs are expensed as incurred. In the period ended December 31, 2020 and 2019 the Company spent $165,000nd $150,000 in research and development which was expenses as spent, respectively.
Income Taxes	(q) Income Taxes Income taxes are accounted for under the assets and liability method. Current income taxes are provided in accordance with the laws of the respective taxing authorities. Deferred income taxes are provided for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is not more likely than not that some portion or all of the deferred tax assets will be realized. The Company has adopted the provisions required by the Income Taxes topic of the FASB Accounting Standards Codification. The Codification Topic requires the recognition of potential liabilities as a result of management’s acceptance of potentially uncertain positions for income tax treatment on a “more-likely-than-not” probability of an assessment upon examination by a respective taxing authority. The Company believes that it has not taken any uncertain tax positions and thus has not recorded any liability.
Net Income (Loss) Per Common Share	(r) Net Income (Loss) per Common Share Basic net income (loss) per common share is computed on the basis of the weighted average number of common shares outstanding during the period. Diluted net income (loss) per common share is computed on the basis of the weighted average number of common shares and dilutive securities (such as stock options and convertible securities) outstanding. Dilutive securities having an anti-dilutive effect on diluted net income (loss) per share are excluded from the calculation. For the periods presented, the diluted net loss per share calculation excluded the effect of Series B preferred stocks and stock options outstanding (see Notes 10, 11 and 12).
Reverse Stock-Split	(s) Reverse Stock-Split On March 2, 2020, the Company filed an amendment to its Articles of Incorporation with the Florida Secretary of State to effect a 300-to-1 reverse stock split of its issued and outstanding, but not authorized, shares of Common Stock, as reported in the Company’s definitive Schedule 14C filed with the Securities and Exchange Commission on December 13, 2019. All disclosures of common shares and per common share data in the accompanying financial statements and related notes reflect the reverse stock split for all periods presented.
Recent Accounting Pronouncements	(t) Recent Accounting Pronouncements In 2016, the FASB issued ASU 2016-2 (Topic 842) which establishes a new lease accounting model for lessees. Under the new guidance, lessees will be required to recognize right of use assets and liabilities for most leases having terms of 12 months or more. Effective January 1, 2019, we adopted this new accounting guidance using the effective date transition method, which permits entities to apply the new lease standards using a modified retrospective transition approach at the date of adoption.
Reclassifications	(u) Reclassifications Certain amounts in the prior year consolidated financial statements have been reclassified to conform to the current year presentation. These reclassification adjustments had no effect on the Company’s previously reported net income.

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2020
Inventory Disclosure [Abstract]
Schedule of Inventories	Inventories consist of: December 31, December 31, Raw materials $ 294,522 $ 708,239 Finished goods 50,432 76,258 Total $ 344,954 $ 784,497

Notes Receivable (Tables)

Notes Receivable (Tables)	12 Months Ended
	Dec. 31, 2020
Receivables [Abstract]
Schedule of Notes Receivable	Notes receivable consist of: December 31, December 31, Note receivable dated November 30, 2015 from Stock Market Manager, Inc, interest at 3% per annum due November 30, 2020 $ - $ 19,389 Note receivable dated February 8,2019 from an employee, weekly installments of $1,200 with interest at 8% per annum. 2,898 4,879 Total 2,898 24,268 Current portion of notes receivable (2,898 ) (24,268 Noncurrent portion of notes receivable $ - $ -

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Summary of Property, Plant and Equipment	Property and Equipment, net, consist of: December 31, 2020 December 31, 2019 Furniture & Fixtures $ 21,727 $ 19,018 Office Equipment 12,378 12,378 Manufacturing Equipment 397,230 355,016 Medical Equipment 776,392 783,782 Leasehold Improvements 26,902 21,603 Total 1,234,629 1,191,797 Accumulated depreciation (239,650 ) (116,555 ) Net $ 994,979 $ 1,075,242

Intangible Assets, Net (Tables)

Intangible Assets, Net (Tables)	12 Months Ended
	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets	Intangible assets, net, consist of: December 31, 2020 December 31, 2019 Video conferencing software acquired by Prosperity in December 2009 $ 30,000 $ 30,000 Enterprise and audit software acquired by Prosperity in April 2008 20,000 20,000 Patent costs incurred by WRAP 6,880 6,880 Hemp license and technology - 1,000,000 CBD technology 482,000 482,000 Platform account contract 131,812 - Hemp processing use 85,200 - Other 3,548 3,548 Total 759,440 1,542,428 Accumulated amortization and Impairment (236,431 ) (202,521 ) Net $ 523,009 $ 1,339,907
Schedule of Estimated Future Amortization Expense	Estimated future amortization expense are as follows: December 31, Amount 2021 $ 120,513 2022 65,591 2023 65,591 2025 65,591 2026 55,449 Thereafter 150,274 Total $ 523,009

Notes and Loans Payable (Tables

Notes and Loans Payable (Tables)	12 Months Ended
	Dec. 31, 2020
Debt Disclosure [Abstract]
Schedule of Notes and Loans Payable	Notes and loans payable consist of: December 31, December 31, Loan payable to Pasquale Ferro, interest at 12% per annum, due December 2020. $ 224,000 $ 30,000 Note payable to brother of Marco Alfonsi, Chief Executive Officer of the Company, interest at 10% per annum, due August 22, 2016. - 5,000 Note payable to Arena Special Opportunities Partners I, LP, due September 10, 2021. 2,675,239 - Note payable to Arena Special Opportunities Fund, LP, due September 10, 2021. 102,539 - Note payable to U.S. Small Business Administration (PPP), interest at 1% per annum. The note matures in January 2023. Payments are deferred for ten months after the end of the covered period. The Note has been submitted to the SBA for forgiveness withing the bank guidelines. 194,940 - Total Notes and Loan Payable 3,196,718 35,000 Less: Unamortized Finance Cost (1,174,247 ) - Less: Current Portion (1,827,531 ) (35,000 ) Long-term Portion $ 194,940 $ -

Stock Options and Warrants (Tab

Stock Options and Warrants (Tables)	12 Months Ended
	Dec. 31, 2020
Share-based Payment Arrangement [Abstract]
Summary of Stock Options and Warrants Activity	A summary of stock options and warrants activity follows: Shares of Common Stock Exercisable Into Stock Options Warrants Total Balance, December 31, 2018 20,167 7,492 27,659 Granted in 2019 56,667 - 56,667 Cancelled in 2019 (167 ) - (167 ) Exercised in 2019 - - - Balance, December 31, 2019 76,667 7,492 84,159 Granted in 2020 1,120,532 3,557,605 4,678,137 Cancelled 2020 - - - Exercised 2020 - - - Balance, December 31, 2020 1,197,199 3,565,097 4,762,296
Schedule of Issued and Outstanding Stock Options	Issued and outstanding stock options as of December 31, 2020 consist of: Year Number Outstanding Exercise Year of Granted And Exercisable Price Expiration 2018 20,000 $ 0.30 2023 2019 56,667 $ 0.30 2022 2020 1,120,532 $ 0.361 2025 1,197,199
Schedule of Issued and Outstanding Warrants	Issued and outstanding warrants as of December 31, 2020 consist of: Year Number Outstanding Exercise Year of Granted And Exercisable Price Expiration 2010 825 $ 300 2020 2018 6,667 $ 13,034 (a) 2023 2020 3,557,605 $ 1,273,623 2025 Total 3,565,097 (a) 110% of the closing price of the Company’s common stock on the date that the Holder funds the full purchase price of the Note.

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Schedule of Provisions for (Benefits from) Income Taxes	The provisions for (benefits from) income taxes differ from the amounts determined by applying the U.S. Federal income tax rate of 21% to pretax income (loss) as follows: December 31, 2020 2019 Expected income tax (benefit) at 21% $ (1,200,467 ) $ (1,239,160 ) Non-deductible stock-based compensation 474,428 923,470 Non-deductible stock-based interest 94,853 - Increase in deferred income tax assets valuation allowance 631,186 315,690 Provision for (benefit from) income taxes $ - $ -
Schedule of Deferred Income Tax Assets	Deferred income tax assets consist of: December 31, December 31, 2020 2019 Net operating loss carryforward 1,931,355 1,300,168 Valuation allowance (1,931,355 ) (1,300,168 ) Net $ - $ -

Segment Information (Tables)

Segment Information (Tables)	12 Months Ended
	Dec. 31, 2020
Segment Reporting [Abstract]
Schedule of Segment Reporting Information	The Company evaluates the performance of the Durable Equipment Products segment based on income (loss) before income taxes, which includes interest income. Durable Equipment Products Three months ended December 31, 2020 Revenue from external customers 367,673 Revenue from other segments - Segment profit 276,226 Segment assets 2,603,379 Twelve months ended December 31, 2020 Revenue from external customers 1,176,220 Revenue from other segments - Segment profit 691,482 Segment assets 2,603,379 Three Months Ended December 31, 2020 Twelve Months Ended December 31, 2020 Total profit for reportable segment $ 278,719 $ 694,828 Other income (expense) - net (2,493 ) (3,346 ) Income before income taxes $ 276,226 $ 691,482

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Lease Payments Under Non-cancellable Operating Leases	At December 31, 2020, the future minimum lease payments under non-cancellable operating leases were: Year ended December 31, 2021 47,055 Year ended December 31, 2022 15,685 Total $ 62,740

Organization and Description _2

Organization and Description of Business (Details Narrative)	Mar. 06, 2020	Mar. 02, 2020	Jun. 04, 2013	Dec. 27, 2010	Dec. 31, 2020	Dec. 28, 2018	Jan. 05, 2015
Stockholders' equity, stock split				10-for-1 forward stock split
Stockholders' equity, reverse stock split	300:1 reverse stock split	300-to-1 reverse stock split	1-for-10 reverse stock split		300:1 reverse stock split
Prosperity Systems, Inc [Member]
Business acquisition, percentage							100.00%
Pure Health Products, LLC [Member]
Business acquisition, percentage						100.00%

Going Concern Uncertainty (Deta

Going Concern Uncertainty (Details Narrative) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Cash and cash equivalents		$ 457,798	$ 46,540
Working capital		1,118,857
Net income loss		5,716,511	5,900,760
Proceeds from sale of common stock		$ 300,000	$ 3,296,700
Subsequent Event [Member]
Proceeds from sale of common stock	$ 2,716,000

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	Mar. 06, 2020	Mar. 02, 2020	Jun. 04, 2013	Dec. 31, 2020	Dec. 31, 2019
Accounting Policies [Abstract]
Bad debt expense				$ 270,919	$ 253,483
Prepaid expenses				1,216,531	2,459,830
Advertising costs				519,922	333,441
Research and development cost				$ 165,000	$ 150,000
Stockholders equity, reverse stock split	300:1 reverse stock split	300-to-1 reverse stock split	1-for-10 reverse stock split	300:1 reverse stock split

Inventories - Schedule of Inven

Inventories - Schedule of Inventories (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Raw materials	$ 294,522	$ 708,239
Finished goods	50,432	76,258
Total	$ 344,954	$ 784,497

Notes Receivable - Schedule of

Notes Receivable - Schedule of Notes Receivable (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Note receivable, total	$ 2,898	$ 24,268
Current portion of notes receivable	(2,898)	(24,268)
Noncurrent portion of notes receivable
Employee [Member]
Note receivable, total	2,898	4,879
Stock Market Manager, Inc [Member]
Note receivable, total		$ 19,389

Notes Receivable - Schedule o_2

Notes Receivable - Schedule of Notes Receivable (Details) (Parenthetical) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Employee [Member]
Note receivable interest rate	8.00%	8.00%
Installments	$ 1,200	$ 1,200
Stock Market Manager, Inc [Member]
Notes receivable due date	Nov. 30, 2020	Nov. 30, 2020
Note receivable interest rate	3.00%	3.00%

Property and Equipment, Net (De

Property and Equipment, Net (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 16,475	$ 12,627

Property and Equipment, Net - S

Property and Equipment, Net - Summary of Property, Plant and Equipment (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
Furniture & Fixtures	$ 21,727	$ 19,018
Office Equipment	12,378	12,378
Manufacturing Equipment	397,230	355,016
Medical Equipment	776,392	783,782
Leasehold Improvements	26,902	21,603
Total	1,234,629	1,191,797
Accumulated depreciation	(239,650)	(116,555)
Net	$ 994,979	$ 1,075,242

Intangible Assets, Net (Details

Intangible Assets, Net (Details Narrative) - USD ($)	Dec. 12, 2020	Jun. 23, 2020	Jun. 22, 2020	Feb. 20, 2019	Jan. 14, 2019	Dec. 31, 2020	Dec. 31, 2019
Shares issued to acquire assets, value						$ 217,012
Cash payments							$ 550,000
Intangible assets, net						$ 0
Mediiusa Group, Inc [Member]
Shares issued to acquire assets	50,000	50,000
Shares issued to acquire assets, value	$ 15,825	$ 69,375
SRAX, Inc [Member]
Shares issued to acquire assets			185,000
Shares issued to acquire assets, value			$ 131,812
License and Acquisition Agreement [Member] | Hudilab, Inc. [Member]
Shares issued to acquire assets					25,000
Shares issued to acquire assets, value					$ 382,500
Asset Purchase Agreement [Member] | Seven Chakras, LLC [Member]
Shares issued to acquire assets				3,333
Shares issued to acquire assets, value				$ 49,500
Cash payments				$ 50,000

Intangible Assets, Net - Schedu

Intangible Assets, Net - Schedule of Intangible Assets and Goodwill (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Patent costs incurred by WRAP	$ 6,880	$ 6,880
Hemp license and technology		1,000,000
CBD technology	482,000	482,000
Platform account contract	131,812
Hemp processing use	85,200
Other	3,548	3,548
Total	759,440	1,542,428
Accumulated amortization and Impairment	(236,431)	(202,521)
Intangible assets, net	523,009	1,339,907
Video Conferencing Software Acquired by Prosperity in December 2009 [Member]
Software acquired	30,000	30,000
Enterprise and Audit Software Acquired by Prosperity in April 2008 [Member]
Software acquired	$ 20,000	$ 20,000

Intangible Assets, Net - Sche_2

Intangible Assets, Net - Schedule of Estimated future amortization expense (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
2021	$ 120,513
2022	65,591
2023	65,591
2025	65,591
2026	55,449
Thereafter	150,274
Intangible assets, net	$ 523,009	$ 1,339,907

Notes and Loans Payable - Sched

Notes and Loans Payable - Schedule of Notes and Loans Payable (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Total Notes and Loans Payable	$ 3,196,718	$ 35,000
Less: Unamortized Finance Cost	(1,174,247)
Less: Current Portion	(1,827,531)	(35,000)
Long-term Portion	194,940
Loan Payable One [Member]
Total Notes and Loans Payable	224,000	30,000
Note Payable One [Member]
Total Notes and Loans Payable		5,000
Note Payable Two [Member]
Total Notes and Loans Payable	2,675,239
Note Payable Three [Member]
Total Notes and Loans Payable	102,539
Note Payable Four [Member]
Total Notes and Loans Payable	$ 194,940

Notes and Loans Payable - Sch_2

Notes and Loans Payable - Schedule of Notes and Loans Payable (Details) (Parenthetical)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Loan Payable One [Member]
Debt instrument, interest rate	12.00%	12.00%
Debt instrument, maturity date	Dec. 31, 2020	Dec. 31, 2020
Notes Payable One [Member]
Debt instrument, interest rate		10.00%
Debt instrument, maturity date		Aug. 22, 2016
Note Payable Two [Member]
Debt instrument, maturity date	Sep. 10, 2021
Note Payable Three [Member]
Debt instrument, maturity date	Sep. 10, 2021
Note Payable Four [Member]
Debt instrument, interest rate	1.00%
Debt instrument, maturity date	Jan. 31, 2023

Preferred Stock (Details Narrat

Preferred Stock (Details Narrative) - USD ($)

Mar. 27, 2021

Mar. 23, 2021

Feb. 08, 2021

Jan. 02, 2021

Mar. 06, 2020

Mar. 02, 2020

Dec. 16, 2019

Aug. 13, 2019

Jun. 07, 2019

May 28, 2019

May 09, 2019

May 01, 2019

Apr. 26, 2019

Jan. 28, 2019

Dec. 28, 2018

Oct. 15, 2018

Jun. 04, 2013

Mar. 31, 2021

May 31, 2019

Mar. 12, 2019

Mar. 25, 2021

Dec. 31, 2020

Mar. 31, 2020

Dec. 31, 2019

Dec. 31, 2020

Dec. 31, 2019

Stock issued during period, shares, issued for services

Stock issued during the period, value

$ 3,296,700

Stockholders' equity, reverse stock split

300:1 reverse stock split

300-to-1 reverse stock split

1-for-10 reverse stock split

300:1 reverse stock split

Subsequent Event [Member]

Stock issued during period, shares, issued for services

130,750

Stock issued during the period, value

$ 5,932,000

Common Stock [Member]

Shares issued during the period

600,000

379,555

Stock issued during the period, value

$ 300,000

$ 3,296,700

Common Stock [Member] | RedDiamond Partners LLC [Member]

Shares issued during the period

35,666

97,607

10,726

23,710

8,581

6,436

67,405

Consultant [Member]

Stock issued during period, shares, issued for services

435,311

27,500

122,258

Consultant [Member] | Common Stock [Member]

Stock issued during period, shares, issued for services

33,333

Pasquale Ferro [Member] | Employment Agreement [Member]

Amortized vesting period

4 years

Series A Preferred Stock [Member]

Number of convertible shares

33,334

33,334

Preferred stock, voting rights

Each share of Series A Preferred Stock is convertible into 33,334 shares of CANB common stock and is entitled to 66,666 votes.

Series A Preferred Stock [Member] | Consultant [Member]

Stock issued in exchange for retirement of shares

1

Series A Preferred Stock [Member] | Stanley L. Teeple [Member] | Employment Agreement [Member]

Stock issued during period, shares, issued for services

1

3

Shares issued during the period

3

Stock issued during the period, value

$ 1,203,000

Amortized vesting period

4 years

Series A Preferred Stock [Member] | Pasquale Ferro [Member] | Employment Agreement [Member]

Stock issued during period, shares, issued for services

5

Series B Preferred Stock [Member]

Preferred stock, voting rights

The shares of Series B Preferred Stock have no voting rights.

Dividend, description

Each share of Series B Preferred Stock has the first preference to dividends, distributions and payments upon liquidation, dissolution and winding-up of the Company, and is entitled to an accrued cumulative but not compounding dividend at the rate of 5% per annum whether or not declared. After six months of the issuance date, such share and any accrued but unpaid dividends can be converted into common stock at the conversion price which is the lower of (i) $0.0101; or (ii) the lower of the dollar volume weighted average price of CANB common stock on the trading day prior to the conversion day or the dollar volume weighted average price of CANB common stock on the conversion day. The shares of Series B Preferred Stock have no voting rights.

Preferred stock, dividend rate, percentage

5.00%

Series B Preferred Stock [Member] | RedDiamond Partners LLC [Member]

Stock issued in exchange for retirement of shares

227,590

25,000

55,263

20,000

15,000

157,105

Preferred Stock C [Member]

Number of convertible shares

25,000

25,000

Stock issued during period, shares, issued for services

Stock issued during the period, value

Preferred Stock C [Member] | Subsequent Event [Member]

Stock conversion description

Each Preferred C was immediately issuable as common at 25 thousand to one so the total issuance was 1,250,000 common shares for each recipient.

Preferred Stock C [Member] | Employment Agreement [Member] | Subsequent Event [Member]

Number of convertible shares

3,750,000

Shares issued during the period

150

Preferred Stock C [Member] | Stanley L. Teeple [Member] | Subsequent Event [Member]

Stock issued during period, shares, issued for services

50

Preferred Stock C [Member] | Stanley L. Teeple [Member] | Employment Agreement [Member] | Subsequent Event [Member]

Shares issued during the period

100

100

Preferred Stock C [Member] | Marco [Member] | Subsequent Event [Member]

Stock issued during period, shares, issued for services

50

Preferred Stock C [Member] | Marco [Member] | Employment Agreement [Member] | Subsequent Event [Member]

Shares issued during the period

100

100

Preferred Stock C [Member] | Pasquale Ferro [Member] | Subsequent Event [Member]

Stock issued during period, shares, issued for services

50

Preferred Stock C [Member] | Pasquale Ferro [Member] | Employment Agreement [Member] | Subsequent Event [Member]

Shares issued during the period

100

100

Series D Preferred Stock [Member]

Preferred stock, voting rights

Each share of Series D Preferred Stock has 10,000 shares of voting rights only pari passu to common shares voting with no conversion rights and no equity participation.

Series D Preferred Stock [Member] | Subsequent Event [Member]

Preferred stock, voting rights

Collectively representing 19,500,000 voting shares.

Each Series D Preferred Share shall have voting rights equal to 10,000 shares of Common Stock, adjustable at any recapitalization of the Company's stock. In the event of a liquidation event, whether voluntary or involuntary, each holder shall have a liquidation preference on a per-share amount equal to the par value of such holder's Series D Preferred Shares.

Shares issued during the period

1,950

Series D Preferred Stock [Member] | Stanley L. Teeple [Member] | Subsequent Event [Member]

Shares issued during the period

600

Series D Preferred Stock [Member] | Marco [Member] | Subsequent Event [Member]

Shares issued during the period

600

Series D Preferred Stock [Member] | Pasquale Ferro [Member] | Subsequent Event [Member]

Shares issued during the period

600

Common Stock (Details Narrative

Common Stock (Details Narrative) - USD ($)

Jul. 29, 2020

Feb. 20, 2019

Feb. 05, 2019

Jan. 28, 2019

Jan. 14, 2019

Mar. 27, 2019

Mar. 17, 2019

Mar. 31, 2021

Mar. 25, 2021

Dec. 31, 2020

Sep. 30, 2020

Jun. 30, 2020

Mar. 31, 2020

Dec. 31, 2019

Sep. 30, 2019

Jun. 30, 2019

Mar. 27, 2019

Dec. 31, 2020

Dec. 31, 2019

Stock issued during the period, value

$ 3,296,700

Stock issued during period, shares, issued for services

Proceeds from issuance of common stock

300,000

$ 3,296,700

Preferred Stock C [Member]

Stock issued during the period, value

Shares issued to acquire assets

Stock issued during period, shares, issued for services

Number of shares issued upon conversion of preferred stock

25,000

25,000

Subsequent Event [Member]

Stock issued during the period, value

$ 5,932,000

Stock issued during period, shares, issued for services

130,750

Proceeds from issuance of common stock

$ 2,716,000

TZ Wholesale LLC [Member]

Stock issued during period, shares, issued for services

6,667

Iconic Brands [Member]

Stock issued during the period

1,000,000

Stock issued during period shares conversion of convertible securities

543,715

Common Stock [Member]

Stock issued during the period

600,000

379,555

Stock issued during the period, value

$ 300,000

$ 3,296,700

Shares issued to acquire assets

285,000

Consultant [Member]

Stock issued during period, shares, issued for services

145,000

111,734

18,061

51,706

Members of Advisory Board, Medical Advisory Board, and Sports Advisory Board [Member]

Stock issued during period, shares, issued for services

100,000

20,319

18,333

13,916

Members of Advisory Board, Medical Advisory Board, and Sports Advisory Board [Member]

Stock issued during period, shares, issued for services

478,715

First Fire Global [Member]

Stock issued during period shares conversion of convertible securities

193,524

Stock Purchase Agreement [Member]

Stock issued during the period

155,241

86,207

Stock issued during period, shares, issued for services

600,000

Proceeds from issuance of common stock

$ 300,000

$ 1,350,600

$ 750,000

License and Acquisition Agreement [Member] | Hudilab, Inc. [Member]

Shares issued to acquire assets

25,000

Asset Purchase Agreement [Member] | Seven Chakras, LLC [Member]

Shares issued to acquire assets

3,333

Executive Employment Agreement [Member]

Stock issued during period, shares, issued for services

30,000

5,000

16,000

4,615

Joint Venture Agreement [Member]

Stock issued during the period

40,247

Investor Purchase Agreement [Member]

Stock issued during period, shares, issued for services

125,000

Proceeds from issuance of common stock

$ 487,500

Junior Convertible Promissory Note Purchase Agreement [Member] | First Fire Global Opportunities Fund, LLC [Member]

Stock issued during period, shares, issued for services

20,000

Junior Convertible Promissory Note Purchase Agreement [Member] | Labrys Fund, L.P [Member]

Stock issued during the period

24,545

Junior Convertible Promissory Note Purchase Agreement [Member] | Eagle Equities, LLC [Member]

Stock issued during the period

20,000

Junior Convertible Promissory Note Purchase Agreement [Member] | First Fire Global Opportunities Fund, LLC [Member]

Stock issued during period, shares, issued for services

185,000

99,508

Platform Access Agreement [Member] | SRAX, Inc [Member]

Stock issued during the period

185,000

Hemp Processing Use Agreement [Member]

Stock issued during period, shares, issued for services

50,000

Hemp Processing Use Agreement [Member] | Mediiusa Group, Inc [Member]

Stock issued during the period

50,000

Returnable share Junior Convertible Promissory Note Purchase Agreement [Member] | Labrys Fund, L.P [Member]

Stock issued during the period

118,000

Exchange Agreement [Member] | Iconic Brands, Inc. [Member]

Shares issued to acquire assets

543,715

Acquisition of Inventory [Member]

Shares issued to acquire assets

478,715

Securities Purchase Agreement [Member] | Arena Special Opportunities Partners I, LP [Member]

Stock issued during the period

394,304

Securities Purchase Agreement [Member] | Arena Special Opportunities Fund, LP [Member]

Stock issued during the period

15,133

Asset Acquisition Agreement [Member] | Subsequent Event [Member]

Stock issued during the period

355,057

Note Conversion Agreement [Member] | Common Stock [Member] | Subsequent Event [Member]

Stock issued during the period

355,250

Note Conversion Agreement [Member] | Common Stock One [Member] | Subsequent Event [Member]

Stock issued during the period

600,000

Employment Agreement [Member] | Subsequent Event [Member] | Preferred Stock C [Member]

Stock issued during the period

150

Number of shares issued upon conversion of preferred stock

3,750,000

Multiple Investors [Member] | Common Stock [Member]

Stock issued during period, shares, issued for services

82,000

Multiple Investors [Member] | Stock Purchase Agreement [Member]

Stock issued during the period

138,107

Stock issued during the period, value

$ 1,196,100

Employees and Officers [Member] | Employee Agreement [Member] | Common Stock [Member]

Stock issued during period, shares, issued for services

3,893

Consultant [Member]

Stock issued during period, shares, issued for services

435,311

27,500

122,258

Consultant [Member] | Common Stock [Member]

Stock issued during period, shares, issued for services

33,333

Medical Advisory Board, and Sports Advisory Board [Member]

Stock issued during period, shares, issued for services

31,335

14,167

Advisory Board, Medical Advisory Board, and Sports Advisory Board [Member]

Stock issued during period, shares, issued for services

70,000

Stock Options and Warrants (Det

Stock Options and Warrants (Details Narrative) - USD ($)	Dec. 29, 2020	Dec. 09, 2020	Oct. 15, 2019	Sep. 09, 2019	Oct. 21, 2018	Jun. 11, 2018	Dec. 31, 2018	Jun. 30, 2018	Dec. 31, 2020	Dec. 31, 2019
Granted options									4,678,137	56,667
Stock options, fair value							$ 118,200	$ 84,000
Stock options, share price							$ 11.82	$ 8.40
Stock options, expected term							5 years	5 years
Stock options, expected volatility rate							221.96%	262.00%
stock options, risk-free interest rate							3.05%	2.80%
Carl Dilley [Member]
Granted options						10,000
Stock issued in exchange for retirement of shares						10,000
Options exercisable for purchase of share						1
Exercisable price per share						$ 0.30
Expiration date						Jun. 11, 2023
Stanley L. Teeple [Member]
Granted options	277,008				10,000
Options exercisable for purchase of share	1
Exercisable price per share	$ 0.36				$ 0.30
Expiration date	Dec. 29, 2025				Oct. 1, 2023
Stock options, fair value									$ 140,997
Stock options, share price									$ .51
Stock options, expected term									5 years
Stock options, expected volatility rate									168.00%
stock options, risk-free interest rate									0.41%
Johnny Mack [Member]
Granted options				26,667
Options exercisable for purchase of share				1
Exercisable price per share				$ 0.30
Expiration date				Sep. 9, 2022
Frederick Alger Boyer [Member]
Granted options			10,000
Options exercisable for purchase of share			1
Exercisable price per share			$ 0.30
Expiration date			Oct. 15, 2022
Stock options, fair value										$ 63,000
Stock options, share price										$ 6.30
Stock options, expected term										3 years
Stock options, expected volatility rate										242.00%
stock options, risk-free interest rate										1.60%
Jr., Ronald A. Silver [Member]
Granted options		12,500	10,000
Options exercisable for purchase of share		1	1
Exercisable price per share		$ 0.50	$ 0.30
Expiration date		Dec. 9, 2025	Oct. 15, 2022
Stock options, fair value									$ 12,500	$ 63,000
Stock options, share price									$ .45	$ 6.30
Stock options, expected term									5 years	3 years
Stock options, expected volatility rate									168.00%	242.00%
stock options, risk-free interest rate									0.41%	1.60%
James F. Murphy [Member]
Granted options			10,000
Options exercisable for purchase of share			1
Exercisable price per share			$ 0.30
Expiration date			Oct. 15, 2022
Stock options, fair value										$ 63,000
Stock options, share price										$ 6.30
Stock options, expected term										3 years
Stock options, expected volatility rate										242.00%
stock options, risk-free interest rate										1.60%
Pasquale Ferro [Member]
Granted options	277,008
Options exercisable for purchase of share	1
Exercisable price per share	$ 0.36
Expiration date	Dec. 29, 2025
Stock options, fair value									$ 140,997
Stock options, share price									$ .51
Stock options, expected term									5 years
Stock options, expected volatility rate									168.00%
stock options, risk-free interest rate									0.41%
Phil Scala [Member]
Granted options	277,008
Options exercisable for purchase of share	1
Exercisable price per share	$ 0.36
Expiration date	Dec. 29, 2025
Stock options, fair value									$ 140,997
Stock options, share price									$ .51
Stock options, expected term									5 years
Stock options, expected volatility rate									168.00%
stock options, risk-free interest rate									0.41%
Marco [Member]
Granted options	277,008
Options exercisable for purchase of share	1
Exercisable price per share	$ 0.36
Expiration date	Dec. 29, 2025
Stock options, fair value									$ 140,997
Stock options, share price									$ .51
Stock options, expected term									5 years
Stock options, expected volatility rate									168.00%
stock options, risk-free interest rate									0.41%

Stock Options and Warrants - Su

Stock Options and Warrants - Summary of Stock Options and Warrants Activity (Details) - shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Beginning balance	84,159	27,659
Granted	4,678,137	56,667
Cancelled		(167)
Exercised
Ending balance	4,762,296	84,159
Warrant [Member]
Beginning balance	7,492	7,492
Granted	3,557,605
Cancelled
Exercised
Ending balance	3,565,097	7,492
Stock Option [Member]
Beginning balance	76,667	20,167
Granted	1,120,532	56,667
Cancelled		(167)
Exercised
Ending balance	1,197,199	76,667

Stock Options and Warrants - Sc

Stock Options and Warrants - Schedule of Issued and Outstanding Stock Options (Details)	12 Months Ended
	Dec. 31, 2020$ / sharesshares
Number of Options Outstanding and Exercisable, Number	1,197,199
Stock Option 2018 [Member]
Number of Options Outstanding and Exercisable, Number	20,000
Number of Options Outstanding and Exercisable, Weighted Average Exercise Price | $ / shares	$ 0.30
Number of Options Outstanding and Exercisable, Expiration year	2023
Stock Option 2019 [Member]
Number of Options Outstanding and Exercisable, Number	56,667
Number of Options Outstanding and Exercisable, Weighted Average Exercise Price | $ / shares	$ 0.30
Number of Options Outstanding and Exercisable, Expiration year	2022
Stock Option 2020 [Member]
Number of Options Outstanding and Exercisable, Number	1,120,532
Number of Options Outstanding and Exercisable, Weighted Average Exercise Price | $ / shares	$ 0.361
Number of Options Outstanding and Exercisable, Expiration year	2025

Stock Options and Warrants - _2

Stock Options and Warrants - Schedule of Issued and Outstanding Warrants (Details)	12 Months Ended
	Dec. 31, 2020$ / sharesshares
Warrant [Member]
Number of Warrants Outstanding and Exercisable, Number	3,565,097
2010 Warrant [Member]
Number of Warrants Outstanding and Exercisable, Number	825
Number of Warrants Outstanding and Exercisable, Weighted Average Exercise Price | $ / shares	$ 300
Number of Warrants Outstanding and Exercisable, Expiration year	2020
2018 Warrant [Member]
Number of Warrants Outstanding and Exercisable, Number	6,667
Number of Warrants Outstanding and Exercisable, Weighted Average Exercise Price | $ / shares	$ 13,034	[1]
Number of Warrants Outstanding and Exercisable, Expiration year	2023
2020 Warrant [Member]
Number of Warrants Outstanding and Exercisable, Number	3,557,605
Number of Warrants Outstanding and Exercisable, Weighted Average Exercise Price | $ / shares	$ 1,273,623
Number of Warrants Outstanding and Exercisable, Expiration year	2025
[1]	110% of the closing price of the Company's common stock on the date that the Holder funds the full purchase price of the Note.

Stock Options and Warrants - _3

Stock Options and Warrants - Schedule of Issued and Outstanding Warrants (Details) (Parenthetical)	12 Months Ended
	Dec. 31, 2020
2018 Warrant [Member]
Percentage of closing price of common stock funding purchase price	110.00%

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Federal income tax rate	21.00%	21.00%
Deferred income tax asset, valuation allowance	$ 1,931,355	$ 1,300,168
Operating loss carryforwards	$ 9,196,924
Effective income tax rate reconciliation, change in deferred tax assets valuation allowance, percent	100.00%
Operating loss carryforwards, 2025	$ 1,369
Operating loss carryforwards, 2026	518,390
Operating loss carryforwards, 2027	594,905
Operating loss carryforwards, 2028	686,775
Operating loss carryforwards, 2029	159,141
Operating loss carryforwards, 2030	151,874
Operating loss carryforwards, 2031	135,096
Operating loss carryforwards, 2032	166,911
Operating loss carryforwards, 2033	311,890
Operating loss carryforwards, 2034	25,511
Operating loss carryforwards, 2035	338,345
Operating loss carryforwards, 2036	381,638
Operating loss carryforwards, 2037	499,288
Operating loss carryforwards, 2038	716,858
Operating loss carryforwards, 2039	1,503,282
Operating loss carryforwards, 2040	3,005,651
Income tax examination, penalties and interest expense

Income Taxes - Schedule of Prov

Income Taxes - Schedule of Provisions for (Benefits from) Income Taxes (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Expected income tax (benefit) at 21%	$ (1,200,467)	$ (1,239,160)
Non-deductible stock-based compensation	474,428	923,470
Non-deductible stock-based interest	94,853
Increase in deferred income tax assets valuation allowance	631,186	315,690
Provision for (benefit from) income taxes	$ 3,304	$ 2,084

Income Taxes - Schedule of Pr_2

Income Taxes - Schedule of Provisions for (Benefits from) Income Taxes (Details) (Parenthetical)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Federal income tax rate	21.00%	21.00%

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Income Tax Assets (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Net operating loss carryforward	$ 1,931,355	$ 1,300,168
Valuation Allowance	(1,931,355)	(1,300,168)
Net

Segment Information (Details Na

Segment Information (Details Narrative)	12 Months Ended
	Dec. 31, 2020Integer
Segment Reporting [Abstract]
Number of reportable segments	1

Segment Information - Schedule

Segment Information - Schedule of Segment Reporting Information (Details) - USD ($)	3 Months Ended	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2020	Dec. 31, 2019
Revenue from external customers		$ 1,709,669	$ 2,305,503
Segment assets	$ 5,691,453	5,691,453	7,214,215
Income before income taxes		(5,713,207)	$ (5,898,676)
Durable Equipment Products [Member]
Revenue from external customers	367,673	1,176,220
Revenue from other segments
Segment profit	276,226	691,482
Segment assets	2,603,379	2,603,379
Total profit for reportable segment	278,719	694,828
Other income (expense) - net	(2,493)	(3,346)
Income before income taxes	$ 276,226	$ 691,482

Commitments and Contingencies_2

Commitments and Contingencies (Details Narrative) - USD ($)

Dec. 29, 2020

Dec. 28, 2020

Jul. 15, 2020

Dec. 08, 2019

Oct. 10, 2019

Oct. 04, 2019

Sep. 06, 2019

May 28, 2019

Dec. 29, 2018

Dec. 29, 2018

Dec. 28, 2018

Nov. 12, 2018

Oct. 21, 2018

Oct. 15, 2018

Feb. 16, 2018

Feb. 12, 2018

Oct. 03, 2017

May 31, 2019

Jun. 30, 2020

Dec. 31, 2019

Sep. 30, 2019

Jun. 30, 2019

Dec. 31, 2020

Dec. 31, 2019

Oct. 31, 2019

Aug. 06, 2018

Sep. 11, 2015

Employee cash compensation per month

$ 2,077,713

$ 2,639,711

Stock issued during period, shares, issued for services

Granted options to purchase stock

4,678,137

56,667

Professional fees

$ 533,213

$ 287,441

Rent expense

234,790

246,968

Operating lease, right-of-use asset

$ 96,980

58,174

$ 96,980

Lease liability

$ 43,506

Estimated incremental borrowing rate

10.00%

Future lease payments

$ 62,740

Sales Revenue, Net [Member] | No Customer [Member]

Concentration risk percentage

10.00%

10.00%

Concentration risk, description

More than 10% of total revenues

Preferred Stock C [Member]

Stock issued during period, shares, issued for services

Series A Preferred Stock [Member]

Preferred stock, shares issued

20

20

20

Pasquale Ferro [Member]

Granted options to purchase stock

277,008

Exercisable price per share

$ 0.36

Marco [Member]

Granted options to purchase stock

277,008

Exercisable price per share

$ 0.36

Stanley L. Teeple [Member]

Granted options to purchase stock

277,008

10,000

Exercisable price per share

$ 0.36

$ 0.30

Executive Employment Agreement [Member]

Stock issued during period, shares, issued for services

30,000

5,000

16,000

4,615

Executive Employment Agreement [Member] | Preferred Stock C [Member]

Preferred stock, shares issued

200

Executive Employment Agreement [Member] | Chief Executive Officer [Member]

Base salary per month

$ 15,000

Incentive stock option plan

100,000

Executive Employment Agreement [Member] | Chief Financial Officer [Member]

Base salary per month

15,000

Incentive stock option plan

100,000

Executive Employment Agreement [Member] | Pasquale Ferro [Member]

Base salary per month

15,000

Incentive stock option plan

100,000

Executive Employment Agreement [Member] | Philip Scala [Member]

Employee cash compensation per month

$ 100,000

Executive Employment Agreement [Member] | Philip Scala [Member] | Preferred Stock C [Member]

Preferred stock, shares issued

20

Executive Employment Agreement [Member] | Marco [Member]

Employee cash compensation per month

$ 10,000

New Employment Agreement [Member] | Marco [Member]

Employee cash compensation per month

$ 15,000

New Employment Agreement [Member] | Marco [Member] | Common Stock [Member]

Number of shares issued as a result of conversion

30,000,000

New Employment Agreement [Member] | Andrew W Holtmeyer [Member]

Employee cash compensation per month

$ 15,000

New Employment Agreement [Member] | Andrew W Holtmeyer [Member] | Common Stock [Member]

Stock issued during period, shares, issued for services

829

Executive Service Agreement [Member] | David Posel [Member]

Employee cash compensation per month

$ 5,000

Executive Service Agreement [Member] | David Posel [Member] | Series A Preferred Stock [Member]

Stock issued during period, shares, issued for services

1

Executive Service Agreement [Member] | Andrew W Holtmeyer [Member]

Employee cash compensation per month

$ 10,000

Executive Service Agreement [Member] | Andrew W Holtmeyer [Member] | Series A Preferred Stock [Member]

Issuance of shares, description

3, 2 and 1 share of Series A Preferred Stock at the beginning of each year

Employment Agreement [Member] | Pasquale Ferro [Member]

Employee cash compensation per month

$ 15,000

Vesting term

4 years

Employment Agreement [Member] | Pasquale Ferro [Member] | Series A Preferred Stock [Member]

Stock issued during period, shares, issued for services

5

Employment Agreement [Member] | Stanley L. Teeple [Member]

Employee cash compensation per month

$ 15,000

Employment Agreement [Member] | Stanley L. Teeple [Member] | Series A Preferred Stock [Member]

Stock issued during period, shares, issued for services

1

3

Vesting term

4 years

New Employment Services Agreement [Member] | Johnny J. Mack [Member]

Employee cash compensation per month

$ 15,000

Granted options to purchase stock

106,667

Number of stock options vesting

26,667

Exercisable price per share

$ 0.30

Accrued employee benefits

$ 13,315

Retention of options

26,667

New Employment Services Agreement [Member] | Johnny J. Mack [Member] | First Anniversary [Member]

Number of stock options vesting

26,667

New Employment Services Agreement [Member] | Johnny J. Mack [Member] | Second Anniversary [Member]

Number of stock options vesting

26,667

New Employment Services Agreement [Member] | Johnny J. Mack [Member] | Third Anniversary [Member]

Number of stock options vesting

26,667

Employee Agreement [Member] | Philip Scala [Member]

Employee cash compensation per month

$ 2,500

Granted options to purchase stock

1,667

Shares issued price per share

$ 0.30

Investor Relations and Advisory Agreement [Member] | Initial 3 Months [Member] | Restricted Stock [Member]

Professional fees

$ 5,000

Investor Relations and Advisory Agreement [Member] | 4-6 Months [Member] | Restricted Stock [Member]

Professional fees

6,250

Investor Relations and Advisory Agreement [Member] | 7 Months and After [Member] | Restricted Stock [Member]

Professional fees

$ 7,500

Consulting Agreement [Member] | Restricted Stock [Member] | Seacore Capital Inc. [Member]

Stock issued during period, shares, issued for services

8,333

Lease Agreement [Member] | Unrelated Third Party [Member]

Initial term of lease

37 months

Monthly rentals for lease year 1

$ 2,922

Monthly rentals for lease year 2

3,009

Monthly rentals for lease year 3

$ 3,100

Renewed Lease Agreement [Member] | Unrelated Third Party [Member]

Monthly rentals for lease year 1

$ 3,807

$ 3,193

Monthly rentals for lease year 2

$ 3,921

3,289

Monthly rentals for lease year 3

$ 3,388

Renewal term of lease

30 months

36 months

Operating lease, right-of-use asset

$ 100,681

Lease liability

90,591

Adjusted modification of lease liabilities

$ 103,260

Commitments and Contingencies -

Commitments and Contingencies - Schedule of Future Minimum Lease Payments Under Non-cancellable Operating Leases (Details)	Dec. 31, 2020USD ($)
Commitments and Contingencies Disclosure [Abstract]
Year ended December 31, 2021	$ 47,055
Year ended December 31, 2022	15,685
Total	$ 62,740

Related Party Transactions (Det

Related Party Transactions (Details Narrative)	12 Months Ended
	Dec. 31, 2020USD ($)
Products sales to related parties	$ 0
LI Accounting Associates, LLC [Member]
Related party expense	$ 64,400

Prior Period Adjustment (Detail

Prior Period Adjustment (Details Narrative)	12 Months Ended
	Dec. 31, 2020USD ($)
Stock Based Compensation [Member]
Adjustment amount	$ 1,308,290
Intangible Asset [Member]
Adjustment amount	$ 283,345

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Mar. 27, 2021	Mar. 23, 2021	Mar. 11, 2021	Feb. 22, 2021	Feb. 08, 2021	Jan. 02, 2021	Mar. 25, 2021	Dec. 31, 2020	Dec. 31, 2019
Preferred stock, shares authorized								5,000,000	5,000,000
Value of stock issued to purchase assets								$ 217,012
Series D Preferred Stock [Member]
Preferred stock, voting rights								Each share of Series D Preferred Stock has 10,000 shares of voting rights only pari passu to common shares voting with no conversion rights and no equity participation.
Preferred Stock C [Member]
Value of stock issued to purchase assets
Subsequent Event [Member] | Asset Acquisition Agreement [Member]
Stock issued during the period							355,057
Payment to acquire assets			$ 355,057
Subsequent Event [Member] | Imbibe Health Solutions, LLC [Member]
Value of stock issued to purchase assets				$ 65,000
Subsequent Event [Member] | KORR Acquisition Group, Inc.[Member]
Debt principal amount						$ 175,000
Debt term						1 year
Debt instrument, interest rate						6.00%
Subsequent Event [Member] | Series D Preferred Stock [Member]
Preferred stock, shares authorized					4,000
Preferred stock, par value					$ 0.001
Preferred stock, voting rights	Collectively representing 19,500,000 voting shares.				Each Series D Preferred Share shall have voting rights equal to 10,000 shares of Common Stock, adjustable at any recapitalization of the Company's stock. In the event of a liquidation event, whether voluntary or involuntary, each holder shall have a liquidation preference on a per-share amount equal to the par value of such holder's Series D Preferred Shares.
Stock issued during the period							1,950
Subsequent Event [Member] | Series D Preferred Stock [Member] | Marco [Member]
Stock issued during the period	600
Subsequent Event [Member] | Series D Preferred Stock [Member] | Pasquale Ferro [Member]
Stock issued during the period	600
Subsequent Event [Member] | Series D Preferred Stock [Member] | Stanley L. Teeple [Member]
Stock issued during the period	600
Subsequent Event [Member] | Series D Preferred Stock [Member] | Philip Scala [Member]
Stock issued during the period	150
Subsequent Event [Member] | Preferred Stock C [Member] | Employment Agreement [Member]
Stock issued during the period							150
Issuance of shares description						Out of the 200 each authorized, 50 have been issued to each employee
Subsequent Event [Member] | Preferred Stock C [Member] | Marco [Member] | Employment Agreement [Member]
Stock issued during the period		100				100
Number of shares authorized to issue						200
Subsequent Event [Member] | Preferred Stock C [Member] | Pasquale Ferro [Member] | Employment Agreement [Member]
Stock issued during the period		100				100
Number of shares authorized to issue						200
Subsequent Event [Member] | Preferred Stock C [Member] | Stanley L. Teeple [Member] | Employment Agreement [Member]
Stock issued during the period		100				100
Number of shares authorized to issue						200